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Summary
This thesis critically evaluates two developments which have both brought 
about major advances in the assessment of glycaemic control in diabetic 
patients. First is the measurement of glycated proteins in the form of glycated 
haemoglobin and serum fructosamine and the second is the use of portable test 
strips and meters for the self-monitoring of blood glucose. Both methods of 
assessment have gained widespread acceptance but there remains a number of 
clinical and methodological problems associated with their use. This thesis 
reviews the literature relating to the use of these tests and describes a number 
of studies demonstrating new benefits and difficulties which exist.
The majority of clinicians now use glycated haemoglobin measurement as their 
principal objective indicator of glycaemic control in diabetic patients. We have 
performed several detailed studies elucidating clinically relevant aspects of 
glycated haemoglobin measurement which can affect the assessment of 
glycaemia in these patients.
The setting of target values for glycated haemoglobin measurement is 
severely hindered by the lack of standardisation in methodology. In an attempt 
to account for this, European guidelines define categories of glycaemic control 
as an HbAi or HbAjc concentration so many standard deviations from a 
particular method’s non-diabetic population mean. Using these guidelines, we 
found that HbAj could classify the same diabetic patients differently to 
HbAic, even when using the same instrument and reference range individuals. 
This new finding led, in part, to a change in the European guidelines for 
glycated haemoglobin targets.
Many commonly used glycated haemoglobin methods include both 
glycated and non-glycated fetal haemoglobin (HbF) in their result. This means 
patients with elevated HbF concentrations (>0.5%) can have spuriously high 
glycated haemoglobin values. We presented the first evidence that insulin
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treated adult patients had a significantly greater prevalence of elevated HbF 
concentrations than either non-insulin treated or non-diabetic controls, thereby 
compounding the problem in this group of patients. In addition, we found that 
HbF increased the apparent imprecision of these assays.
Discrepancies exist when comparing glycated haemoglobin and serum 
fructosamine as indicators of glycaemic control. We found that in newly 
diagnosed Type II diabetes, fructosamine only showed a correlation with HbAj 
after glucose control had stabilised and not during the period of changing 
glycaemia. However, because changes in fructosamine preceded those of 
HbAi, the ratio of fructosamine/ HbAi was able to predict the change in HbAi 
in the forthcoming month. Thus, parallel measurement of fructosamine with 
HbAi provided additional information on the future trend of a HbAi 
concentration.
A further reason for disparity between fructosamine and glycated 
haemoglobin was established when investigating the effects of ageing on 
glycation in non-diabetic subjects. Mean HbAic values rose with increasing 
subject age while fructosamine and fasting plasma glucose values did not. 
Consequently, when Type II diabetic patient samples were classified according 
to European HbAic guidelines, significantly fewer patients were in good 
control and more in poor control when a young reference population was used 
compared to an age matched one. Thus, age related reference intervals may be 
required for glycated haemoglobin measurement.
Using test strips and meters to measure blood glucose has become widespread 
amongst diabetic patients in the community and in the monitoring of acutely ill 
hospital patients. We have documented studies which describe the effect on 
glucose measurement of variations in several physiological parameters. We 
also describe how new technology is improving glucose meter measurement.
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In vitro variations of sample haematocrit have been shown to be a source of 
error in several glucose meter systems. Red cell count and mean cell volume 
are intimately related to haematocrit, so it makes it impossible to distinguish if 
the test strip error is due to haematocrit variations per se or to changes in the 
number of red cells. We found that in groups of individuals with different 
mean cell volumes, meter error was still related to the haematocrit of the 
sample rather than its red cell count.
Having established this, 10 patients undergoing cardiopulmonary bypass 
(whose haematocrits routinely fall to 20% intraoperatively) were investigated 
to determine the effect of in vivo variations in haematocrit. Changes in test 
strip glucose accuracy were found to be consistent with those shown previously 
in vitro.
While the use of whole blood to measure glucose is convenient, it is not 
possible, unlike plasma or serum, to tell if a sample is in any way haemolysed. 
We showed that extreme sample haemolysis can affect several glucose meter 
systems, while even modest degrees of red cell lysis were found to give 
clinically inaccurate results when using the Accutrend instrument.
Most glucose meter systems use the enzyme glucose oxidase as their basis 
of measurement. Like all enzymes, it may be affected by changes in ambient 
pH and substrate concentrations. We demonstrated that variations in sample 
pH and p 0 2 can cause clinically important errors, especially when using 
biosensors such as the ExacTech glucose meter. Therefore, use of such a meter 
in acidotic or hypoxic patients may be inappropriate.
New blood glucose meter systems offer many potential advantages over 
previous systems. One such meter, the One Touch II, showed impressive 
performance when used in a laboratory environment. In a six week ward 
evaluation, the One Touch II demonstrated better meter accuracy, fewer blood 
glucoses too high to be measured and a greater user preference compared to the 
existing Glucometer II system. When used by out-patients, average values in
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the glucose meter’s memory were found to relate more closely to HbAjc 
values than random clinic glucose measurements.
The ability to accurately assess present and prior glucose control by the means 
described has undoubtedly benefited the treatment of patients with diabetes 
mellitus. This thesis has demonstrated that although technological advances 
have led to improvements, interpretation of these indices cannot yet be used as 
a sole substitute for clinical judgement.
Chapter 1
Glycaemic Control Assessment: 
A Historical Background and 
Review of Current Methodologies.
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1.1 Introduction
The non-enzymatic and irreversible binding of glucose to the amino acids of 
proteins has long been known to food chemists as the ‘browning reaction’.1 
While this glycation process may alter the structure and function of proteins 
and thus be relevant to the small vessel complications of patients with diabetes 
mellitus,2’3 glycation of haemoglobin and serum proteins (in the form of 
fructosamine) has become an important means of objectively assessing 
glycaemic control in diabetic patients.
The measurement of blood glucose itself remains central to the diagnosis of 
diabetes mellitus as well as being an important adjunct to glycated proteins in 
the monitoring of patients. Recent technological advances involving glucose 
test strips and meters has moved much of the monitoring of blood glucose from 
the laboratory into the hands of diabetic patients and health care staff.
The scope of this thesis relates to the clinical uses and difficulties which 
exist in using glycated haemoglobin, serum fructosamine and glucose test 
strips in the assessment of metabolic control in diabetes. Although other 
indicators of glycaemia (such as glycated albumin4 and 1,5-anhydroglucitol5) 
have been proposed only these three are routinely used in clinical practice.
This chapter describes the historical development and uses of these tests, 
their underlying mechanisms of formation, and the current methods used for 
their measurement.
1.2 Historical Background
1.2.1 Glycated Haemoglobin
In 1962, Huisman and Dozy reported an increase in some of the minor 
fractions of haemoglobin in four diabetic patients who had been treated with 
tolbutamide.6 Using column chromatography, they called these fractions ‘fast’ 
haemoglobins since they eluted before the main component, HbA0. Their
25
increase was attributed to a reaction of tolbutamide to haemoglobin. However, 
attempts to reproduce this phenomenon in vitro proved unsuccessful.6
In 1967, an abnormal negatively charged haemoglobin band was observed 
by cellulose acetate electrophoresis in two patients being screened for 
abnormal haemoglobins at Tehran University hospitals. Both patients were 
suffering from diabetes mellitus. Further investigation by Rahbar found another 
47 cases of the abnormal band, all occurring in patients with poorly controlled 
diabetes. The finding of a ‘diabetic haemoglobin component’ was thus reported 
in 1968.7
Soon it was demonstrated that the diabetic component had a 
chromatographic characteristic similar to that of HbAjc, a minor Hb 
component described by Schnek and Schroeder in 1961 and found in non­
diabetic adults in a proportion of 1-4%.8 Structural studies later established that 
the diabetic haemoglobin was indeed identical with HbAjc.9
Nearly a decade passed following Rahbar’s discovery before a flurry of 
clinical studies were published which showed that the increased proportions of 
HbAjc in diabetic patients could be used as a reliable index of glycaemic 
control over the preceding 6-8 weeks. The studies demonstrated correlation of 
glycated haemoglobin with other known indicators of diabetic control such as 
24-hour urinary glucose excretions,10 plasma ‘glucose brackets’,11 daily mean 
plasma glucose12 and the area under the curve of the glucose tolerance test.13 
Following these studies, and despite considerable methodological difficulties 
in measurement (see Chapter 2.2), acceptance of the use of glycated 
haemoglobin by diabetologists and other health care workers was rapid. The 
main reason for its attraction to clinicians was clear: for the first time they had 
an apparently simple tool which could give a completely objective assessment 
of a patient’s glucose control.14 Thus treatment regimes could now be changed 
without relying solely on a patient’s description of symptoms or home 
urine/blood test results.
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As well as its use in monitoring diabetic patients, it was hoped that 
measurement of glycated haemoglobin could also be used as an alternative to 
the laborious and inconvenient glucose tolerance test (GTT) in diagnosis. First 
studies to assess this were hindered by the non-uniformity of GTT criteria, 
resulting in discrepant results depending on which glucose cut-offs were 
used.15’16 Even following the widespread recognition of WHO criteria for the 
GTT, and the undertaking of numerous studies, there continues to be some 
debate as to the usefulness of glycated haemoglobin in diagnosis and screening. 
A recent review of 25 studies confirmed that in a subject with a mildly elevated 
glycated haemoglobin level the test was not specific or sensitive enough to 
reliably distinguish between normality, impaired glucose tolerance or 
diabetes.17 However, it is possible this is more a reflection on the poor 
reproducibility of the GTT18 than any shortcoming of the glycated haemoglobin 
assay. In addition, some evidence suggests that the test may be more 
dependable when measured in younger (30-59yrs) rather than elderly 
subjects.19
Soon after the first clinical studies it was realised that glycated 
haemoglobin measurement could prove to be useful in answering one of the 
fundamental questions in diabetes, namely, are long-term microvascular 
complications of the disease related to the degree of control of 
hyperglycaemia?20 Although early studies had suggested such a link,21’22 the 
technical advances of glycated haemoglobin, capillary blood glucose 
measurement and intensified insulin regimes now made it possible to conduct 
more meaningful trials.23 Indeed, once available, glycated haemoglobin 
measurement became the cornerstone of treatment evaluation in all such 
studies.24 In particular, the largest and most comprehensive study, the Diabetes 
Control and Complications Trial (DCCT),25 showed conclusively that 
glycaemic control as assessed by glycated haemoglobin can predict the risk of 
developing microvascular diabetic complications in Type I patients. As a
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consequence, the usefulness of the assay was vindicated and its increased use 
recommended. 23’24’26’27 Moreover, it was suggested that the cost of using the 
test in routine clinical practice was likely to be offset by much larger savings 
due to the decreased need for procedures such as laser photocoagulation 
therapy, renal dialysis and renal transplantation.23 The continued use of 
glycated haemoglobin measurement in diabetes assessment would thus seem 
assured.
1.2.2 Serum Fructosamine
By contrast with glycated haemoglobin, serum fructosamine measurement was 
established as a useful indicator of glycaemic control (over the previous 1-3 
weeks) after a relatively short gestation. New Zealanders, Johnson, Metcalf and 
Baker were the first investigators to propose the use of a simple colorimetric 
assay for the assessment ‘serum glycosylprotein’ concentrations in 1982 28 
They based their assay on the ability of serum protein ketoamine linkages to 
glucose being able to act as reducing agents in alkaline solution. These protein 
ketoamines were generically termed ‘fructosamines’, not because of the 
involvement of fructose but because the resulting compound had structural 
similarities to this sugar.29 Since all serum proteins can form ketoamines 
through glycation, fructosamine was found to give a similar indication of 
glycaemic control to that found when measuring total glycated protein and 
glycated albumin.30'33 However, in contrast to assaying the latter, fructosamine 
could be measured by spectrophotometer instruments found in most clinical 
biochemistry laboratories. Therefore, the assay initially gave the promise of 
being a less expensive and quicker alternative to the majority of glycated 
haemoglobin analyses methods used at the time.34’35 Indeed, early cross 
sectional studies seemed to show good correlations between fructosamine and 
glycated haemoglobin,34'38 but subsequent studies have since shown that 
marked discrepancies can exist between the two measures,39-43 not least
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because they measure glycaemia over different time-scales. Nevertheless, the 
shorter time period measured by fructosamine has especially leant itself to use 
in pregnant diabetic patients44 where frequent objective monitoring is essential 
for the health of both mother and fetus.45,46
Fructosamine, like glycated haemoglobin, has also been evaluated as a tool 
for the diagnosis of diabetes. After initial optimism47,48 studies have since 
found it to lack the sensitivity and specificity required of a screening test.49'53 
Moreover, as a substitute for the GTT, it seems to be inferior to measuring 
glycated haemoglobin.52,53
1.2.3 Monitoring of Blood Glucose
Until the early 1980’s, self monitoring of glycaemic control for most 
diabetic patients was limited to the measurement of glucose concentrations in 
urine samples. Many patients found this method to be insensitive, particularly 
due to the problems associated with the renal threshold for glucose. Indeed, at 
the time, adjustment of insulin dosages according to urine tests was likened to 
‘driving a car on roads with a 30mph limit with a speedometer that only begins 
to work at greater than 70mph’.54 The measurement by patients of blood rather 
than urine glucose was perceived as a means of surmounting these problems.
Although for many years the accurate and precise measurement of blood 
glucose had been achievable in the laboratory setting,55 the technology for 
portable instrumentation did not become available until the early 1970’s. The 
first advance was in the development of ‘dry’ chemistry techniques which 
obviated the need for liquid reagents in glucose measurement. With this 
approach, the blood sample itself was the solvent in which the chemical 
reaction took place. The earliest demonstration of such technology for glucose 
measurement occurred over 30 years ago using glucose oxidase ‘Dextrostix’ 
strips from Ames which were similar in principle to those still in use today.56,57 
By the early 1970’s, both Ames (now Bayer) and Boehringer Mannheim (BM)
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had developed disposable test strip systems using this technique. Before 
reading, removal of blood from the strip was required either by blotting (BM) 
or with water (Ames). In these first strips visual assessment of the colour 
change (and therefore the blood glucose measurement) was at best 
semiquantitative, allowing only an estimate of low, medium or high values. 
Reflectance meters were then introduced by both companies which gave the 
promise of more accurate and consistent measurement.58 However, these were 
bulky, expensive and not easy to use. For example, the Ames ‘Eyetone’ meter 
cost around £200, weighed 1.7kg, measured 18x 1 lx  5cm, required mains 
operation, a 30 minute warm-up period, calibration before each sample and 
employed a needle scale for reading.59
Despite these disadvantages, a number of papers in 1978 demonstrated the 
potential usefulness of the devices when used at home by diabetic 
patients.54,60,61 It was hoped that the ability to measure near physiological blood 
glucose concentrations would allow more diabetic patients to achieve this 
degree of control.54 It also meant that glucose concentrations could be assessed 
accurately without recourse to frequent hospital admission, especially in 
pregnant diabetic patients.60,62
Nevertheless, it was recognised that the potential market for meters would 
only be realised if they became less expensive and genuinely portable. In 1978, 
the Glucoscan (Lifescan Inc) was introduced which was relatively small (lOx 
6.4x 1.3cm), light (0.2kg), used rechargeable batteries, had a light emitting 
diode readout, factory calibration and could use Ames test strips.59 Other 
companies followed suit and there then followed a period of steady 
improvement in the products of all manufacturers in terms of ease of use and 
cost. However, a significant advance occurred in 1987 with the introduction of 
‘non-wipe’ systems by Lifescan Inc and Medisense Ltd which allowed glucose 
measurement without the need for blotting (or the now obsolete washing) of 
sample from the test strip. One of these meters, the ExacTech from Medisense,
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was particularly elegant. It used a pen sized meter which, instead of detecting a 
colour change in a reagent strip, employed a disposable biosensor for the 
electrochemical detection of blood glucose.63 Most new glucose meters are 
now ‘non-wipe’ and several also include features such as automatic timing of 
the test, time and date stamping of results, and the recording of these results in 
the meter memory.
The next major advance in blood glucose monitoring is likely to be in the 
form of ‘non-jab’ measurement using near infra-red techniques64 but as yet no 
commercial system has been developed.
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1.3 Glycated Haemoglobin and Fructosamines:
Structure and Formation
1.3.1 Glycated Haemoglobin
Human haemoglobin demonstrates marked heterogeneity, mainly as a 
consequence of post-translational changes due to the non-enzymatic binding of 
various carbohydrates in a process known as glycation. Glycation occurs via a 
carbohydrate such as glucose reacting in its free aldehyde form with a 
haemoglobin molecule to form the Schiff-base compound, aldimine (Figure 
1.1).65 The formed aldimine can then meet one of two further fates: it can 
either dissociate back to its component carbohydrate and haemoglobin or, in a 
process that is 60-fold less rapid, it can undergo an intermolecular 
transformation known as the Amadori rearrangement to form a stable glycated 
ketoamine product (Figure 1.1).
Haemoglobin glycation occurs at several sites, namely, the amino terminal 
of both its a  and P-chains, as well as at certain s-amino groups.66 However, it 
is only the modification at the N-terminal valine amino acid of the p-chain 
which imparts enough negative charge to the haemoglobin molecule to allow 
separation of the respective haemoglobins by charge-dependent techniques. In 
contrast, glycation at sites other than the p-chain amino terminus results in a 
compound with a charge not dissimilar to non-glycated haemoglobin and so is 
indistinguishable by these methods. However, this portion, which accounts for 
about half of all haemoglobin glycation, can be detected if glycation-specific 
‘total glycated haemoglobin’ methods such as affinity chromatography are used 
(see Chapter 1.4.1).
The charge-separated haemoglobins of normal adult HbA0 are jointly 
known as haemoglobin A \ (HbAj). Improved techniques have allowed further 
separation of HbAj into its constituent parts, HbAiaj, HbAja2, HbAjb» and 
HbAjc. Glucose is the carbohydrate in the major fraction, HbAjc, whilst other
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carbohydrates, some of which have still to be established with certainty, 
constitute the other fractions (Table l .l) .67
Glycation of haemoglobin occurs continuously throughout the 120 day 
lifetime of the red cell,68 so the eldest cells will be most glycated and the 
youngest least.69 However, all ages of cells will have been exposed to recent 
levels of glycaemia while only the eldest cells will also have been exposed to 
glucose levels from 4 months previously. Therefore, the more recent the period 
of glycaemia, the larger its influence will be on the glycated haemoglobin 
value. Consequently, it has been suggested that half of a HbAjc value is 
attributable to changes in glycaemia over the preceding month, a further 
quarter is due to the month prior to that, with the remaining quarter a reflection 
of months 3 and 4.70
1.3.2 Fructosamines
As mentioned in Chapter 1.2.2, serum fructosamine measurement is a measure 
of total glycated serum proteins. These glycated proteins are formed via a 
Schiff base and Amadori rearrangement in the same way as glycated 
haemoglobin. The fructosamine assay measures glycation at all sites on a 
protein molecule and so is not dependant on changes in molecular charge 
caused by glycation.
The major serum protein, albumin, has a half life substantially shorter than 
haemoglobin at around 20 days. Serum fructosamine therefore appears to 
reflect time-integrated glycaemia over a period of only 1-3 weeks.71
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1.4 Glycaemic Control Assessment Methodologies
1.4.1 Glycated Haemoglobin Methods
Methods in routine use for the measurement of glycated haemoglobin separate 
the molecule on the basis of either its charge, structure or antigenic properties. 
Table 1.2 gives the methods and instruments that are in routine use as 
described by the United Kingdom National External Quality Assessment 
Scheme (UK NEQAS).
The most popular means of measurement rely on the increased negative 
charge found in the glycated haemoglobin molecule to distinguish it from its 
non-glycated form. These assays include electrophoresis and ion-exchange 
chromatography.72 The latter method is becoming increasingly popular with the 
development of rapid (as short as 4 minutes between samples) dedicated high 
performance liquid chromatography (HPLC) instruments which are much less 
labour intensive than electrophoresis. These new analysers have also made 
feasible the measurement of glycated haemoglobin ‘on-site’ at diabetic out­
patient clinics.73 New high-resolution HPLC instruments are now emerging 
which appear to show the relative lack of specificity that currently used HPLC 
‘reference’ systems have for measuring HbAjc.74
Boronate affinity chromatography separates glycated haemoglobin on the 
basis of its structure rather than charge. In this assay, separation occurs by the 
carbohydrate moieties present on glycated haemoglobin binding by 
condensation to the affinity reagent, di-hydroxyboronate.75 This method is 
specific for all glycated haemoglobins irrespective of molecular charge or the 
site of glycation on the haemoglobin molecule. In addition, it is also able to 
detect the glycated portion of haemoglobin in patients with haemoglobin 
variants such as HbS, HbC or HbF. Thus, the term ‘total glycated 
haemoglobin’ has been used in describing this type of assay. Nevertheless, 
despite some reservations,74 these glycated haemoglobin values are usually
o
Cx>
f f i
<x>
f f i
£
&
eb o
eS
s
o
^  su  2
£
c
■ s a
ox>r£><
c/3
</>
<dV-i
_§ &4b (U
o' 60
£  .3  g  o p S
J i  o  u
W U  X
CO
60
C
C / 3
• rH
C / 3^ o »-h yo g
Mh • jt<
o  Q 
&  a  
8 |
^  o
«s
<+hc
U  co
X>
<D
3
C/3
cd
CD
C/3
cd
<D
C/3
cd
*-i
O
•8
CDa
+->
O
*-i
C/3
73
O3
<Da
a
•
jdo
'3boa
CD
cd
43
73
CD
cdo
'3b
bD.a
£0 
43
C/3
CD
1 H
CN
CD
H in
vo
lv
em
en
t 
in 
the
 
Un
ite
d 
Ki
ng
do
m 
N
at
io
na
l 
Ex
te
rn
al
 Q
ua
lit
y 
A
ss
es
sm
en
t 
Sc
he
m
e.
34
expressed as ‘HbAjc equivalents’ by comparison with those obtained using an 
HPLC instrument. Like HPLC, some affinity chromatography methods have 
now been automated with ‘on-site’ use of instruments possible.76
More recently, immunoassays have been developed for the measurement of 
HbAjc. The Dako Novoclone is an enzyme immunoassay performed on 
microtitre plates employing a monoclonal antibody raised against a 
haemoglobin molecule with glucose attached to the N-terminal valine.77 Such a 
system is only suited to batch analysis in a laboratory but a portable instrument, 
the DCA 2000 analyser from Bayer Diagnostics, has been used successfully in 
our diabetic clinic.78 It’s assay is based on latex immuno-agglutination 
inhibition methodology and uses a disposable cartridge to measure each sample 
individually. In a situation similar to the affinity chromatography assays, both 
these immunoassay methods are calibrated with material to which HbAic 
values have been assigned using HPLC.
1.4.2 Fructosamine Methods
The fructosamine assay relies on the ability of serum Amadori compounds to 
directly reduce nitroblue tetrazolium (NBT) to the tetrazinolyl radical NBT+, 
which disassociates to yield a highly coloured formazan dye in an alkaline 
environment.79 The reaction rate is followed by measuring the increase in dye 
absorbance between 10 and 15 minutes incubation at 530nm wavelength.
While NBT is reduced, the oxidation degeneration product of the Amadori 
compound would appear to be D-glucosone.80
Since originally introduced, the commercial assays from Boehringer 
Mannheim and Roche underwent modifications in 1991 by including a 
detergent and uricase in the reagent, and by increasing the concentrations of 
both the carbonate buffer (from 0.1M to 0.2M) and the dye (from 0.25mmol/L 
to 0.48mmol/L).81 This has helped reduce the effect of lipaemic and 
hyperuricaemic samples as well as diminishing protein matrix effects (see
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Chapter 2.3.3).82 At the same time, the detection wavelength of absorption 
changed from 530 to 550nm. Also, glycated polylysine replaced 
deoxymorpholinofructose (DMF) as the assay calibrant (see Chapter 2.3.1).83 
To accompany these wholesale changes, the units for fructosamine 
measurement changed from mmol/L to pmol/L with the results from the two 
assays not being directly comparable.84
1.4.3 Glucose Test Strip Methods
Nearly all glucose test strips employ the enzyme glucose oxidase as their basis 
of measurement. The strips are impregnated with glucose oxidase, peroxidase 
and a chromogenic dye. Glucose in the blood sample reacts with the enzyme 
system to bring about a colour change in the chromogen which is proportional 
to the concentration of glucose in the original sample (Figure 1.2a). The colour 
change can either be read visually and compared to a colour chart, or read with 
the aid of a reflectance meter and a digital readout. The glucose oxidase 
enzyme system has also been adapted for measuring blood glucose electro- 
chemically.63 This method uses ferrocene as the electron mediator of the 
enzyme rather than molecular oxygen thus allowing the rate of reaction to be 
followed by a change in electrical current (i.e. amperometrically) rather than by 
a change in colour. More recently, Bayer has broken with tradition and 
introduced the Glucometer 4 meter which uses the enzyme hexokinase rather 
than glucose oxidase (Figure 1.2b). Hexokinase is already used by laboratories 
as a reference method for the measurement of plasma glucose. This enzyme 
also has the advantage of being less susceptible to compounds which can 
interfere with glucose oxidase measurement (see Chapter 2.4.3).
(a)Glucose Oxidase
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HCOH HCOH
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Fig 1.2 (a) Test strip glucose oxidase enzyme system,
(b) Test strip hexokinase enzyme system.
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Chapter 2
A Review of Factors Affecting 
the Interpretation of Glycaemic Control.
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2.1 Introduction
The ability to accurately assess present and prior glucose control has 
undoubtedly benefited the treatment of patients with diabetes mellitus. 
Clinicians can now set goals of glycaemic control for their patients by using 
glycated haemoglobin or fructosamine values while patients can empower 
themselves to meet these aims through the self-monitoring of blood glucose. 
However, errors in any of these measurements may either lead to the setting of 
unattainable goals or conversely the acceptance of spuriously good glucose 
control.
As these measurements of glucose control become further established it is easy 
to assume that any faults which may have existed must now have been 
removed. This chapter reviews the problems which can confound the 
assessment of glycaemia when using these tests.
2.2 Factors Influencing Glycated Haemoglobin 
Measurement
2.2.1 Lack of standardisation
A wide range of instruments and methods are available for glycated 
haemoglobin measurement (see Chapter 1.4.1). It is perhaps not surprising that 
instruments which measure different species (such as either HbAj, HbAjc or 
total glycated haemoglobin) tend to produce results which are not directly 
comparable. However, due to a lack of standardisation, even methods which 
purport to measure the same analyte can have widely differing reference 
intervals and give varying results for patient samples. Indeed, quality control 
returns to UK NEQAS showed poor between-laboratory agreement for 
glycated haemoglobin with an overall coefficient of variation of 20%.85 As 
such, this lack of standardisation is regarded as one of the major drawbacks
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that limits the clinical utility of glycated haemoglobin measurements86 and 
both the British Diabetic Association87 and the National Diabetes Data Group88 
see solving the problem as a major priority.
A number of different approaches have been used to address this issue. 
European guidelines have suggested that glycaemic control be classified 
according to how many standard deviations (SD’s) a patient’s HbAj or HbAjc 
lies from the non-diabetic mean value for the particular assay.89 Within 3SD of 
the non-diabetic mean is defined as good control, between 3 and 5SD is 
borderline and outwith 5SD is poor. Other groups have proposed alternatives 
such as comparing local laboratory values with those obtained when the same 
samples are measured by the DCCT central HbAjc laboratory.90 Another 
approach, used with a degree of success in the Netherlands, has been to use 
lyophilised calibrators to calibrate local instruments to produce similar 
values.91’92 However, all these suggestions have not been without problems.
For example, lyophilised specimens were found to be incompatible with total 
glycated haemoglobin assays and delay in the transport of samples between 
laboratories produced variations in results. In addition, all the proposed 
schemes, with the exception of the European guidelines, have the disadvantage 
of being time-consuming and expensive to maintain.
Full standardisation of glycated haemoglobin measurements is not expected 
until at least the end of the decade.86 In the meantime, proposals such as the 
European guidelines are likely to continue to be the only means of comparing 
results obtained from different laboratories using differing methods.
2.2.2 Haemoglobinopathies
Normal adult haemoglobin is assembled from a-, P-, y- and 5 chains to form 
HbA0 (a2P2), fetal haemoglobin, HbF (a2Y2) and HbA2  (oc252).68 As described 
above in Chapter 1.3.1, glycation of normal adult haemoglobin (HbA0) leads to 
the formation of HbAj and HbAjc. However, point mutations in the primary
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structure of the p-chain can give rise to structural variants of haemoglobin, 
such as those found in HbS (p6 glu->val^ jjbC (p6 glu-»lys) HbE (p26 §lu^  
!ys). Also, impaired synthesis of p-chains lead to conditions such as P- 
thalassaemia and hereditary persistent HbF. Patients with any of these 
haemoglobinopathies are likely to form glycated products such as HbSjc, 
HbCjc or HbEjc either in addition to or instead of HbAjc.93
The influence of abnormal haemoglobins on glycated haemoglobin 
measurement is variable depending on the method of analysis used.94 In 
general, specific measurements of HbAj or HbAjc in homozygous 
haemoglobinopathies will fail to detect any glycated haemoglobin and will 
necessitate measurements of derivatives such as HbSic or HbCjc. In 
heterozygous haemoglobinopathies (e.g. HbAS, HbAC) or haemoglobin 
synthesis variants (e.g. p-thalassaemia), the same specific assays are likely to 
underestimate the degree of haemoglobin glycation by an amount dependent on 
the ratio of normal:abnormal haemoglobin. Examples of these specific methods 
include the electrophoretic, HPLC and the previously mentioned immunoassay 
methods. In some of these systems the problem is easily identified because the 
abnormal haemoglobins separate to form additional peaks, but in other HPLC 
and immunoassay techniques these abnormal haemoglobins may be 
indistinguishable from HbA0.95 The only assays able to give meaningful 
measurements in these conditions are those based on affinity chromatography 
because of their ability to measure glycation at any site of any haemoglobin 
molecule. However, even measurement of this ‘total glycated haemoglobin’ 
appears to be problematic since it would seem haemoglobins S and C glycate 
faster than native HbA0, thus leading to overestimation of the glycated 
haemoglobin value in the heterozygous (e.g. HbAC) state.96
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2.2.3 Fetal Haemoglobin
Fetal haemoglobin (HbF) has relevance to the measurement of glycated 
haemoglobin beyond that of abnormal haemoglobins. It is present 
physiologically as 75-100% of total haemoglobin in newborn children then 
declines during childhood to less than 1% in most adults.97 However, for 
reasons unknown, this decline can be variable and incomplete, even in patients 
known not to have hereditary persistent HbF. The finding would be of no 
consequence was it not for the fact that HbF, whether glycated or not, co- 
migrates or co-elutes with the glycated haemoglobin peak of many commonly 
used electrophoretic and HPLC methods.98’99 Thus, any detectable percentage 
of HbF in a patient sample is likely to be included in the HbAj or HbAjc 
result of these methods leading to falsely elevated results.98’100,101 Moreover, in 
paediatric diabetic patients, increased concentrations of HbF have been found 
compared to non-diabetic controls, thereby exacerbating the problem in these 
patients.102
2.2.4 Haemoglobin Derivatives
Haemoglobin derivatives arise from post-translational modification of 
haemoglobin. Examples are those resulting from reactions with glucose (to 
form glycated haemoglobin), urea-derived isocyanate (to form carbamylated 
haemoglobin) and acetylsalicylic acid (to form acetylated haemoglobin).103 As 
is the case for abnormal haemoglobins, glycated haemoglobin methods are 
affected differently by the latter two derivatives. Both electrophoretic and 
HPLC methods show increases in glycated haemoglobin values with increasing 
degrees of uraemia as a consequence of rising concentrations of carbamylated 
haemoglobin.104'106 For approximately every 15mmol/L of urea, glycated 
haemoglobin measurements increase by 1%.106 In contrast, affinity 
chromatography and enzyme immunoassay methods seem free from 
interference.106,107 Acetylated haemoglobin affects the same methods as the
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carbamylated form, although in patients on chronic low doses of aspirin (200- 
300mg/day), the effect would appear negligible.106 However, in rheumatoid 
patients receiving 4g/day, rises in glycated haemoglobin of 1.5% have been 
found when using HPLC methods.108
2.2.5 Labile Haemoglobin
Many original electrophoretic and liquid chromatography methods for 
measuring glycated haemoglobin showed marked fluctuations in results with 
acute changes in blood glucose.109’110 This was due to these methods being 
unable to distinguish between HbAj/HbAic and the intermediate aldimine or 
Schiff base.111 This latter compound, also known as the labile haemoglobin 
fraction or pre-HbAjc, has for over a decade been removed chemically112 and 
should now only be of historical interest.
2.2.6 Decreased Red Cell Survival
Processes which lessen mean red cell life to shorter than 120 days will reduce 
the availability of haemoglobin for glycation. As a consequence, lower 
glycated haemoglobin values have been recorded in patients with chronic renal 
failure113, immune haemolytic anaemia114 and homozygous 
haemoglobinopathies.115 This phenomenon is independent of the method of 
analysis used and cannot be easily corrected, so often the only recourse is to 
use an alternative method of glycaemic control assessment such as the 
measurement of serum fructosamine.115
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2.3 Factors Influencing Serum Fructosamine 
Measurement
2.3.1 Lack of Standardisation
Calibration of the fructosamine assay has proved to be a major problem 
because of the lack of a trustworthy standard or calibrator. The obvious 
candidate, glycated serum albumin, has proven to be extremely difficult to 
manufacture to a known and reproducible amount.116 Even if feasible, storage 
in a matrix suitably similar to human serum would pose further difficulties. As 
an alternative, the original fructosamine assay used the less desirable 
deoxymorpholinofructose (DMF). Although similarities between the reaction 
of NBT with DMF and with human serum existed, the reaction kinetics and 
absorption spectra were markedly different. The situation has since improved 
with the adoption of synthetically created glycated polylysine as a calibrator in 
new fructosamine kits. Reaction of this compound with NBT produces an 
absorption spectrum more akin to human serum than that found with DMF. It 
is hoped that this improvement may now have resolved most fructosamine 
calibration problems.29
2.3.2 Serum Proteins
Debate continues as to whether fructosamine concentration should be corrected 
for serum protein concentration. Empirically, it would not seem surprising that 
a measurement of glycated proteins is apt to be influenced by serum protein 
concentrations. Opponents of this view argue that, theoretically, glucose 
concentration is the rate-limiting step in the glycation reaction because 
available protein lysine residues will always be vastly in excess of reactive 
open-chain (carbonyl) glucose molecules.117 However, much evidence has 
accumulated to suggest this is unlikely to be the case. An in vitro study has 
actually found that the amount of fructosamine formed is in first-order relation
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to albumin concentration and not glucose.118 The authors of the study 
postulated that as carbonyl glucoses were removed by glycation, more glucose 
molecules isomerised to the open-chain form to maintain equilibrium.
Clinical evidence would also support the fact that, even with improvements 
in the assay, pathological changes in serum proteins can affect fructosamine.119 
For example, patients with cirrhosis of the liver, the nephrotic syndrome120’121 
and hyperthyroidism (associated with increased protein turn-over)122 all 
demonstrate reduced values. Even normoalbuminaemic Type I diabetic patients 
have shown diurnal variation in fructosamine levels closely related with 
changes in their serum protein concentration.123 However, there has been 
consensus agreement that in patients with a serum albumin concentration 
greater than 30g/L, the effect will be negligible.119
It is generally assumed that albumin makes the largest contribution to total 
glycated protein concentration, but it has also been suggested that certain 
proteins such as IgA may have a greater influence on fructosamine values than 
others such as albumin, presumably because they glycate at different rates. This 
disproportionate contribution of IgA, either in well subjects124 or in patients 
with paraproteinaemias125, may thus partly explain why the involvement of 
serum proteins in fructosamine measurement remains controversial.
2.3.3 Interfering Substances
The original fructosamine assay was subject to interference from reducing 
substances other than ketoamine linkages, especially uric acid and ascorbic 
acid. Common photometric interferents such as bilirubin, haemolysis and 
lipaemia also interfered. Bilirubin and lipaemia caused increased fructosamine 
values while haemolysed samples produced falsely low ones 29 The 
introduction of new fructosamine kits not only changed the calibrators, but also 
addressed hyperuricaemic samples by including a uricase, and lipaemic 
samples by including surfactant detergents. Increasing the concentration of
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NBT in the reaction mixture also reduced the error due to interfering reducing 
substances other than uric acid.116 Thus the new assay is significantly more 
robust than previously.
2.3.4 Body Mass Index
An unusual but consistent finding has been observed whereby obese diabetic 
patients and non-diabetic individuals have been found to have lower 
fructosamine values than lean ones.126-128 Reductions of up to 25% have been 
noted in subjects with a body mass index (BMI) >30 kg/m2 despite having 
identical HbAjc and fasting glucose values.126 Serum from these patients has 
also been found to glycate serum proteins at a slower rate in vitro than serum 
from less obese individuals.128 However, the precise mechanism for this 
phenomenon remains unknown.
2.4 Factors Influencing Blood Glucose Test Strip 
Measurement
2.4.1 Lack of Standardisation
Whilst the use of whole blood in a clinical setting has the advantage of being 
convenient, whole blood glucose measurement, unlike plasma glucose, lacks a 
defined standard against which other methods can be calibrated.129 However, 
the Yellow Springs Instrument (YSI) glucose analyser has become a de facto 
standard used by most glucose meter manufacturers to calibrate their 
instruments. The choice of the YSI owes more to it being one of the first 
widely available whole blood glucose instruments than to any analytical 
superiority. Indeed, because the YSI measures blood glucose indirectly (i.e. 
after dilution of the sample), results are liable to be affected by deviations in 
plasma protein concentrations, high lipid levels and the haematocrit of the 
blood specimens.129 Thus, the lack of an agreed standard, and the limitations of
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the adopted YSI instrument means that whole blood glucose measurements 
cannot be as universally concordant as that of plasma.
2.4.2 User Errors
Although newer glucose meters have helped address specific problems, many 
errors in test strip glucose measurement are still attributable to the user. These 
include errors due to the size and placement of the blood sample, the timing of 
the test and wiping of blood from the test strip.130 Any other conceivable 
mistake in measurement such as the use of glucose-contaminated hands or 
inappropriate storage of test strips is sure to become apparent when any group 
of diabetic patients or health care staff are allowed use of the analysis.
Visual reading of test strips adds another source of error which can 
considerably reduce the accuracy of measurements in general use.130 Patients 
tend to cluster their results around the standard colours on the container, 
despite instructions to interpolate.131 Colour blindness and impaired colour 
discrimination, either inherited or acquired as a result of diabetes,132 can also 
lead to difficulty in strip interpretation.133,134
Another important source of user ‘error’ is the falsification by patients of 
results obtained by glucose self-monitoring. In the first study to highlight the 
problem, 19 diabetic patients were given meters which had (unknown to them) 
memory chips built in. It was found that in 30% of glucose record diaries the 
patient had fabricated results, in 8% results had been omitted and in 26% there 
was disagreement between the meter result and that written in the diary.135 The 
authors concluded that about a third of patients could not be relied on to keep 
unambiguous monitoring diaries, a figure confirmed in subsequent studies.136
2.4.3 Analytical Errors
Analytical compromises are unavoidable when using a glucose meter 
instrument costing £30-50 and test strips priced at £0.25 each. Indeed, it is
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perhaps surprising how accurate and precise these meters can be considering 
such cost restraints. Nevertheless, some of the compromises present can lead to 
clinically important errors in glucose measurement.
Variations in blood sample haematocrit have been shown to be a source of 
inaccuracy in many blood glucose systems.137'140 In general, blood samples 
adjusted to have a low haematocrits can give spuriously high glucose results 
and vice versa. This effect can be well in excess of that found when using 
instruments such as the YSI analyser. For example, for every 10% change in 
sample haematocrit the glucose concentration measured by Bayer Glucostix 
can vary by approximately 20%.137
When the glucose oxidase enzyme is used for glucose measurement, 
reducing agents found in the blood sample can interfere by a competitive effect 
on the redox detection system.141 Hence, exogenously given substances such as 
ascorbic acid, paracetamol and salicylate as well as large amounts of 
endogenous uric acid, urea and creatinine can lead to falsely low results with 
many systems.141
Meter measurement of glucose test strips has been replacing visual reading 
mainly because of its ease of use and potential for more accurate results. 
However, case reports have documented examples where extremely high 
glucose values have given considerably lower results on the Boehringer 
Mannheim Reflolux S meter while manual reading of the strip has confirmed 
the gross hyperglycaemia.142,143 With more meters being introduced which do 
not have any form of visual backup, there may be more scope for such errors to 
pass unnoticed.
Lastly, because glucose meters measure glucose concentration indirectly, 
they may (like the YSI instrument) underestimate glucose concentrations in 
extremely hyperproteinaemic or hyperlipidaemic patients.144
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Chapter 3
Thesis Methodologies.
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3.1 Introduction
This chapter presents a description of the methods of glycaemic control 
assessment used in common by the studies in this thesis. Thus, the laboratory 
assessment of glycated haemoglobin, serum fructosamine and blood/plasma 
glucose are included. The other methods of analysis peculiar to each study have 
been included in their relevant chapters.
3.2 Blood sampling
3.2.1 Glycated Haemoglobin Samples
All analyses of glycated haemoglobin were collected in containers with 
potassium ethylenediaminetetraacetic acid (K^EDTA) anticoagulant. All 
samples were stored at 4°C and analysed within 3 days of collection.
3.2.2 Serum Fructosamine Samples
Fructosamine samples were collected in containers without anticoagulant. 
Serum was separated after centrifugation at 2500xg for 7 minutes. Serum was 
stored at 4°C and analysed within 1 week of collection.
3.2.3 Plasma Glucose Samples
Plasma glucose samples were collected in blood tubes containing potassium 
oxalate and sodium fluoride as an anticoagulant and an inhibitor of glycolysis 
respectively. Plasma was separated as above and glucose analysis performed 
within four hours of sampling.
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3.2.4 Whole Blood Glucose Samples
Whole blood glucose samples were collected into either heparinised glass 
capillary tubes or, in the case of the Analox instrument, into capillary tubes 
containing sodium fluoride/potassium oxalate and sodium nitrite. All samples 
were analysed within 15 minutes of collection.
3.3 Glycated Haemoglobin
3.3.1 HbA] by Electrophoresis
Electrophoretic measurement of HbA \ used the Coming Glytrac system 
(Ciba Coming Diagnostics Ltd, Halstead, Essex, UK). The whole blood sample 
(50pL) is incubated at 37°C with 150pL of labile removing haemodialysing 
reagent. One microlitre of haemolysate is dispensed onto an agar film which 
undergoes electroendosmosis in a citrate buffer. The film is then dried and 
scanned by a Coming 720 densitometer at 420nm which displays the value of 
HbA] as a percentage of the total haemoglobin. Between-batch imprecision 
(coefficient of variation, CV) was 4.33% at a mean HbA] concentration of 
8 .22%.
3.3.2 HbA] by High Performance Liquid Chromatography
Measurement of HbA j by high performance liquid chromatography 
(HPLC) used a Hi-AutoAlc, model 8121 instrument (Kyoto Daiichi Kagakiu 
Co. Ltd., Japan, distributors Biomen Ltd, Finchampstead, Berkshire, UK). 
Three microlitres of whole blood is added to 450pL of haemolysing solution 
which contains a labile removing reagent (tetrapolyphosphate at 48°C for 2 
minutes at pH6). An HPLC ion exchange chromatographic column with a 
separation time of 4 minutes is used. Elutions are detected by a dual 
wavelength photometer (415 and 500nm) and measurements of HbA j, HbAjc
50
and HbF obtained by the integration of their corresponding peaks. Each 
measurement is expressed as a percentage of the total haemoglobin. Between- 
batch CV was 4.1% at a mean HbA] concentration of 12.1%.
3.3.3 HbA] r by High Performance Liquid Chromatography
Haemoglobin A jc measurement by HPLC used the same instrument as that 
described in Chapter 3.3.2. Both HbA] and HbAjc measurements are obtained 
by the one sample injection. Between-batch CV was 2.2% at a mean HbAjc 
concentration of 9.2%.
3.3.4 HbA]r by DC A 2000 Immunoassay
The Ames/Bayer DCA 2000 (Bayer Diagnostics, Basingstoke, UK) portable 
immunoassay instrument was also used for HbA]c measurement. As described 
in Chapter 1.4.1, monoclonal antibody to HbA]c is used in a latex- 
agglutination immunoassay.
In this assay, total haemoglobin is measured first by reaction with 
potassium ferricyanide and then thiocyanate to form thiocyan-methaemoglobin. 
The quantity of haemoglobin is proportional to the absorbance of this 
compound at 531nm wavelength. For the measurement of specific HbA]c, an 
agglutinator (a synthetic polymer containing multiple copies of the 
immunoreactive portion of HbA] c) causes agglutination of latex coated with 
HbA]c-specific mouse monoclonal antibody. This agglutination reaction 
causes increased light scattering which is measured as an increase in 
absorbance at 531nm. Haemoglobin A jc in the blood specimen competes for 
the limited number of antibody-latex binding sites causing an inhibition of 
agglutination, a decreased scattering of light, and therefore a reduced
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absorbance at 53 lnm that can be quantified by the instrument using a pre­
programmed calibration curve.
All the necessary reagents are contained in a single reagent cassette, and 
following the introduction of a 1 pL whole blood sample into the cassette all 
the reagent mixing and the measurements are carried out by the instrument 
within 9 minutes. Again, HbAjc is expressed as a percentage of total 
haemoglobin. Between-batch CV during the study period was 4.2% at a mean 
HbAic concentration of 5.4%
3.3.5 HbAjr  by Novoclone Immunoassay
The Dako Novoclone HbAjc (previously Novo Nordisk Diagnostics Ltd, 
Cambridge, UK, now Dako Ltd, High Wycombe, UK) system employs more 
traditional immunoassay techniques. In this assay, 500 pL of red cells are first 
washed, lysed in water then oxidised with ferricyanide to remove the labile 
fraction. The haemolysate is diluted in buffer and then added to the wells of a 
microtitre plate and incubated for 30 minutes. The wells are emptied and then 
incubated with lOOpL of biotinylated HbAjc antibody for 60 minutes. A 
further lOOpL of avidin-peroxidase conjugate is added followed by another 60 
minute room temperature incubation. Following washing of the wells, 
remaining bound horse radish peroxidase reacts with added 
o-phenylenediamine to produce a colour whose absorbance is measured at 492 
and 620 nm by a microtitre plate reader. The percentage HbAjc is calculated 
from a standard curve using standards to which HbAic values have been 
assigned using HPLC.
The assay is novel in that the total haemoglobin concentration is not 
measured. Instead, it is assumed the same quantity of any haemoglobin will 
bind to the microtitre plate, a fact that explains why this assay produces low
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results in patients with haemoglobinopathies (see Chapter 2.2.2). Between- 
batch CV for this assay was 5.0% at mean HbAjc concentration of 6.4%.
3.4 Serum Fructosamine
As mentioned in Chapter 1.4.2, the fructosamine assay has undergone 
improvements since its inception. One study in this thesis (Chapter 8) used the 
original fructosamine kit (Roche Diagnostica, Welwyn Garden City, UK). 
Analyses were performed on a Cobas-Bio centrifugal analyser (Roche 
Diagnostica) using the protocol outlined in Chapter 1.4.2. This assay had a 
reference interval for non-diabetic individuals of 2.1-2.8 mmol/L. Between- 
assay CV was 3.6% at 4.1 mmol/L.
Following the introduction of the improved Fructosamine Plus kit (Roche 
Diagnostica), the units for fructosamine changed. The reference interval was 
now 202-276 pmol/L, but the same Cobas Bio instrument was used for 
analysis. The between-batch CV for this kit was 1.9% at 304 prnol/L.
3.5 Blood Glucose Reference Instruments
3.5.1 Introduction
In the studies described in this thesis, laboratory glucose measurements were 
performed on both plasma and whole blood. In general, studies relating to 
glucose test strip measurement were performed on whole blood while those on 
the studies of glycated haemoglobin and fructosamine used plasma. A range of 
these instruments were used as described below.
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3.5.2 The YSI Glucose Analyser
The Yellow Springs Instrument Model 23AM (YSI Ltd, Hampshire, UK) was 
used to measure whole blood glucose. A 25pL blood sample is injected into the 
instrument and diluted in buffer. A membrane embedded with the enzyme 
glucose oxidase metabolises glucose in the sample to form hydrogen peroxide 
as one of its products (see Figure 1.2a). A polarised platinum anode oxidises 
the hydrogen peroxide thus:
H20 2 - >  2H+ + 0 2 + 2e-
The glucose concentration is proportional to the current produced at the 
anode. The instrument was calibrated using standard solutions before each 
batch of samples.
3.5.3 The Beckman II Glucose Analyser
The Beckman analyser (Beckman, Yellow Springs, Ohio, US) also uses the 
enzyme glucose oxidase as its basis for measurement. However, in contrast to 
the YSI instrument, it measures the consumption of oxygen in the sample 
rather than the formation of hydrogen peroxide. This oxygen consumption is 
measured using an oxygen electrode. The instrument is only suited to the 
measurement of plasma since the presence of oxyhaemoglobin in the 
erythrocytes of whole blood will interfere with measurements. Between-batch 
CV for this instrument was less than 2%.
3.5.4 The Analox GM9 Glucose Analyser
The Analox GM9 analyser (Analox Instrument Ltd, Hammersmith, London, 
UK) was used for the measurement of whole blood glucose. Like the Beckman 
instrument it measures the consumption of oxygen following reaction of
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sample glucose with glucose oxidase. Unlike the Beckman it can measure both 
plasma and whole blood samples. This is achieved by collecting the blood 
sample (at least 5pL) in capillary tubes containing nitrite which converts 
haemoglobin to methaemoglobin and thus prevents oxyhaemoglobin affecting 
the measurement. As with the YSI, calibration of the instrument was performed 
before each batch of samples.
3.5.5 The Dimension Analyser
Plasma glucose was also measured on the routine laboratory ‘Dimension’ 
instrument using a hexokinase method (Du Pont, Herts, UK), and monitoring 
formation of NADPH by the increase in absorbance at 340nm wavelength 
(Figure 1.2b). Between-batch CV for this method was <2%.
3.6 Blood Glucose Test Strips and Meters
Studies in this thesis have used a wide variety of glucose test strips and meters. 
The meters (with their respective test strips) include: the One Touch II 
(Lifescan Ltd, High Wycombe, Bucks, UK); the Reflolux II and Accutrend (12 
second glucose strip) (both Boehringer Mannheim UK, Lewes, East Sussex, 
UK); the Glucometer IIM, Glucometer Gx and Glucometer 4 (all Bayer UK 
(Ames Division), Basingstoke, UK); and the ExacTech and Companion 2 (both 
Medisense Ltd, Abingdon, Oxon, UK). These meters are shown in Figure 3.1.
Each meter was calibrated according to the manufacturers instructions and 
operated using test strips within their expiry date. All meters were checked for 
accuracy using manufacturers recommended solutions and, where applicable, 
test paddles.
All systems bar the Glucometer 4 employ the glucose oxidase enzyme 
system as their basis for measurement as described in Chapter 1.4.3. The
Reflolux I! M  J~  ^ Q
Figure 3.1 Test strip blood glucose meters.
Top picture (L to R): One Touch II, Glucometer 4, Accutrend 
(Bottom): ExacTech 
Bottom picture (L to R) Glucometer Gx, Reflolux II
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Glucometer 4 is instead based on the hexokinase enzyme. Only the ExacTech 
and Companion 2 meters measure glucose amperometrically rather than 
colorimetrically. The Companion 2 test strip differs from the ExacTech by 
having an additional ‘blanking’ electrode as a means of reducing chemical 
interference in the measurement. The older test strips belonging to the Reflolux 
and Glucometer II/Gx meters require wiping of blood from the test strip while 
all other meters used ‘non-wipe’ strips.
Uses of the meters peculiar to a particular study are described in the 
methods sections of the relevant chapters.
3.7 Statistical Analysis
All statistical analyses were performed using ‘Statgraphics’ and ‘Statgraphics 
Plus’ software (Statistical Graphics System. Rockville MD: Statistical 
Graphics Corporation Inc. 1986, 1995). Statistical tests used are described in 
their respective thesis chapters.
Chapter 4
The Effects of Fetal Haemoglobin on the 
Interpretation of Glycated Haemoglobin 
Measurements.
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4.1 Introduction
Fetal haemoglobin (HbF) can co-elute or co-migrate with the glycated 
haemoglobin peak of several HbAi and HbAjc methods (see Chapter 2.2.3). 
Thus HbF, whether glycated or not, will be included in the glycated 
haemoglobin result of these assays. At the time of this study, the most popular 
method of measuring HbAj in the UK was by electrophoresis.145’146 Even now, 
it continues to be used in many hospital laboratories. Unfortunately, this assay 
is one of those known to be influenced by fetal haemoglobin concentrations.98
A known example of the problem associated with HbF occurred in a 63 
year old male Type II patient attending the out-patient clinic at our hospital. 
Insulin treatment had been considered because his HbAj by electrophoresis of 
13% had consistently indicated poor glycaemic control. Discrepancies between 
these HbAj results and glucose monitoring prompted the measurement of HbF 
by a routine insensitive electrophoretic technique. This estimated the patient as 
having 5% HbF, meaning that his true HbAj was nearer to 8%, and that his 
glycaemic control was, in fact, good.
In 1990, a high performance liquid chromatography (HPLC) glycated 
haemoglobin instrument, the Biomen HA-8121, was introduced to the UK. As 
well as being able to measure HbAj and HbAjc, it was also able to 
simultaneously separate and measure small quantities of HbF in whole blood. It 
thus had the potential to be a useful tool in accurately assessing the effect that 
patient fetal haemoglobin has on the methods which include HbF in their 
measurement.
At the same time, European consensus guidelines for glycated haemoglobin 
measurement were becoming generally accepted and applied in clinical 
situations. In their original form, the guidelines defined good glycaemic control 
as a HbAi or HbAic within 2 standard deviations (SD’s) of the non-diabetic p . 
mean value i.e. within the reference range or interval. Borderline control was 
between 2 and 4 SD’s and poor control outwith 4 SD.147 Although the
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recommendations were originally aimed at non-insulin-dependent patients, 
their scope was subsequently broadened to include insulin treated and Type I 
patients as well.148
No prior study had accurately determined the concentrations of HbF found 
in adult diabetic patients. The present study describes the use of the Biomen 
instrument in establishing the prevalence of HbF in insulin treated and non­
insulin treated diabetic adults compared to a group of non-diabetic controls. In 
addition, the effect that HbF concentrations may have on the clinical 
interpretation of electrophoretic HbAj results are evaluated with particular 
regard to the use of the consensus guidelines.
4.2 Methods
4.2.1 Patients
107 diabetic patients were chosen randomly from the outpatient clinic at 
Gartnavel General Hospital, Glasgow. They comprised 50 insulin treated (27 
men, 23 women, median age 40, range 13-77 years) and 57 non-insulin treated 
(31 men, 26 women, median age 64, range 36-94 years) patients. Fifty seven 
non-diabetic control subjects (34 men, 23 women, median age 59, range 12-90 
years) were also included.
4.2.2 Study Design
Whole blood was collected for the measurement of HbA j, HbAjc and HbF in 
all 107 patients and serum was also separated for fructosamine analysis in 82 
of these.
HbAj was measured by electrophoresis (HbAjg) (Ciba Coming 
Diagnostics Ltd) and high performance liquid chromatography (HbAjjqpLc) 
(Hi-AutoAlc, model 8121, Biomen UK Ltd) methods. Haemoglobin A \c and 
HbF were measured concurrently by the same HPLC instrument.
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Plasma glucose was measured by a glucose oxidase method (Beckman 
Instruments Inc).
4.2.3 Statistical Analysis
Statistical analysis was performed using Kruskal-Wallis one-way analysis of 
variance, chi-squared tests with Yates correction and Gaussian tail area 
probabilities where appropriate. The correlation coefficients were calculated by 
the least squares method.
4.3 Results
4.3.1 HbF in Study Patients
Insulin treated diabetic patients had a mean HbF concentration of 0.40% (range 
0-2.7%) and non-insulin treated diabetics 0.30% (range 0-4.7%) (p=0.056 
using Kruskal Wallis). Control patients had a mean HbF concentration of 
0.34% (range 0-3.1%) (NS compared to the diabetic group).
Patients are considered to have elevated concentrations of HbF when the 
value is >0.5%.102 23/50 (46%) of insulin treated patients had increased 
concentrations of HbF compared to 13/57 (23%) of controls {y} = 5.42, 
p<0.02). In non-insulin treated diabetic patients, 14/57 (25%) had increased 
concentrations (NS compared to controls).
HbF concentrations did not correlate with measures of glycaemic control as 
represented by HbAjg, HbAjdqpLC or fructosamine.
Age and sex made no significant difference to the prevalence of increased 
HbF concentrations in insulin treated, non-insulin treated or control groups.
4.3.2 HbF and Glycated Haemoglobin Method Comparison
HbA ip  correlated with HbA] by HPLC in insulin treated patients (r=0.84, 
pO.OOl) and non-insulin treated patients (r=0.93, p<0.001). The correlations
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in these two groups improved when HbAjg (where HbF comigrates with 
HbAi) was compared to the sum of HbFppppc and HbAijjpLC (r=0.92 and 
r=0.95 respectively) (Figure 4.1).
4.3.3 HbF and Comparisons Between Fructosamine and Glycated 
Haemoglobin
Serum fructosamine correlated best with HbAicjjpLC (r=0.76, p<0.001) 
followed by HbAi^pLC (r=0.72, p<0.001) and (HbAi+HbF)p[PLC (r=0.68, 
p<0.001). Correlation was least with HbAig (r=0.64, p<0.001).
4.3.4 HbF and Glycated Haemoglobin Assay Imprecision
In calculating the between-batch imprecision of an assay, quality control (QC)
material is analysed with each assay run of patient samples. The spread of QC
results is often expressed as a coefficient of variation (CV) defined as:
Standard Deviation of QC results x 100% 
Mean Value of QC results
To illustrate the possible effect of HbF on the imprecision of the
electrophoretic assay, HbF-free quality control material was used. Using this
preparation, the estimated between-batch imprecision (CV) during 107 assay
runs was 4.3% at a mean HbAj concentration of 8.22% (Figure 4.2a). Unlike
QC material, however, patient samples contain variable concentrations of HbF
which are included in HbAjg measurements. To simulate the effect that
variable patient HbF may have on assay imprecision the concentrations of
HbFjqpLC measured in 107 diabetic patients were randomly added to the
previous 107 electrophoretic quality control results. The mean calculated HbAj
concentration rose to 8.57% and the CV to 8.33%. (Figure 4.2b). Thus, if 107
patient samples with the same HbAj were analysed instead of QC material,
both the spread of results (imprecision) and the mean value (bias or accuracy)
would increase.
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4.4 Discussion
These results show that insulin treated patients have increased fetal 
haemoglobin concentrations compared to non-insulin treated and non-diabetic 
controls and that these values are not dependent on the age, sex or glycaemic 
control of the subject. In a paediatric population, HbF concentrations have 
previously been demonstrated to be higher in insulin-dependent diabetes than 
in non-diabetic controls but it was assumed that these raised values declined 
into adulthood.102 Our observations would suggest that this may not be the case 
in some patients.
Elevated levels of HbF have been described in autoimmune diseases such 
as pernicious anaemia149 and thyrotoxicosis.150 Since Type I diabetes mellitus 
also has an autoimmune component,151 it is perhaps not surprising that raised 
HbF concentrations may be present in this disease.
The reason for increased HbF concentrations remains speculative. Delayed 
transition from HbF to adult HbA has been described in the hyperinsulinaemic 
infants of diabetic mothers,152 but with abnormal HbF concentrations appearing 
unrelated to age in this study, a reactivation of the HbF gene in insulin treated 
patients seems more probable.
This study has also shown that concentrations of HbF not only affect those 
patients with high HbF measurements (and therefore spuriously high HbAi) 
but have a general effect on the imprecision and accuracy of the electrophoretic 
assay as a whole. Haemoglobin F added an average of 0.35% to the HbAj 
results thereby affecting assay accuracy. Since inter-patient HbF is variable, 
this added a random error which also increased the spread of results. The 
simulated experiment demonstrated the magnitude of this effect, showing that 
the between-batch CV (imprecision) for the assay was almost double that 
suggested by the use of quality control material alone.
When the true imprecision of the assay is so great it can markedly affect the 
classification of glycaemic control if European HbAi guidelines are used.
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Applying these guidelines to the electrophoretic assay, where the local 
reference interval is 4.8-7.8%, good control (<2SD from non-diabetic mean) is 
<7.8%, borderline (2-4SD) is 7.8 to 9.3%, and poor control (>4SD) is >9.3%.
If an acceptable assay run is defined as one which has a quality control sample 
result within two standard deviations from a quality control mean then, by our 
simulated experiment, a patient with a ‘true’ HbAj of 8.22% may have an 
electrophoretic measurement reported as being between 7.14% and 10.00% 
(Figure 4.2b). Using the above definition this corresponds to either good, 
acceptable or poor glycaemic control!
Looked at from a different perspective, fetal haemoglobin can also 
influence the use of this assay as a screening test for diabetes. If the sample 
with a HbAi of 8.22% was to be screened, 12% of acceptable assay runs would 
classify this patient as having a HbAi within the non-diabetic reference 
interval. More worryingly, it has recently been advocated that the diagnosis of 
diabetes in patients with borderline fasting plasma glucose values (6.4- 
7.8mmol/L) could usefully be made if their glycated haemoglobin 
measurement was >1% above the ‘upper limit of normal’.17 Not only may 
patients with high concentrations of HbF be wrongly diagnosed as diabetic, but 
the imprecision of the electrophoretic assay itself will increase 8% of 
acceptable assay runs by at least this 1%.
This study also demonstrated that comparisons between different glycated 
haemoglobin methods can be influenced by whether the assay includes HbF in 
results or not. When the electrophoretic HbAj measurement was compared 
with HPLC, the correlation between the 2 measurements in insulin treated 
patients was less (r=0.84) than when the measured HbF concentration was 
included (r=0.92). Thus, in laboratories employing the electrophoretic method 
of HbA i measurement, the potential effect of HbF concentrations must be 
taken into account when comparing different methods of analysis.
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Comparisons between serum fructosamine and HbAj as different 
assessments of glycaemic control have shown wide variations in the degrees of 
correlation between the two measurements, varying from r=0.91153 to a 
complete lack of correlation40 (see also Chapter 1.2.2). The discrepancy in the 
time period of integrated glycaemia measured by the two assessments (1-3 
weeks for fructosamine, 6-8 weeks for HbAi) likely to be partially 
responsible. However, an important new finding in the present study is that 
comparisons differ markedly with the method of glycated haemoglobin 
measurement and that HbF inclusion accounts for some of the discrepancies. 
Correlation between fructosamine and HbAi was least for the electrophoresis 
method (r=0.64). Using HPLC, the correlation was least when including 
measured HbF, ((HbAi+HbF)pjpLc), but improved when measuring just 
HbAi HPLC (r^O.68 and r=0.72 respectively). Correlation with fructosamine 
was greatest with HbAicfjpLC; (r=0.76). Thus, future comparisons of the two 
assessments may benefit if precise HbAic assays are used instead of older, 
more imprecise glycated haemoglobin methods.
As new instruments for glycated haemoglobin analysis become available, it 
is tempting to assume that the problems associated with fetal haemoglobin will 
diminish as the electrophoretic method of analysis is gradually supplanted. 
However, it is probable that other glycated haemoglobin assays which include 
HbF will be affected in a similar way. Thus, the problems highlighted here will 
be applicable to other commonly used systems, such as the Coming 
‘Glycomat’ HPLC analyser. At present, the Glycomat competes with the 
Biomen HPLC analyser for being the most commonly sited glycated 
haemoglobin instrument in UK laboratories.
In conclusion, the popular electrophoretic method of HbA \ measurement 
may be more inaccurate and imprecise than quality control data suggests 
because of the presence of fetal haemoglobin in patient samples. This problem 
may be compounded in insulin treated patients because of their increased
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prevalence of high HbF concentrations. As a consequence, there is reduced 
agreement between results from this assay and those obtained from other 
glycated haemoglobin methods as well as a poorer relationship with serum 
fructosamine concentrations. More importantly, the use of glycated 
haemoglobin as a means of assessing and diagnosing diabetes is prone to being 
less reliable when HbF-including methods are used.
In the years following the publication of this study,154 two further studies 
have since confirmed the finding of raised HbF concentrations in adult insulin 
treated patients. The first found 23 of 60 adult Type I patients to have raised 
HbF concentrations compared to 9 of 60 control subjects.155 More recently, a 
study involving 1,104 diabetic patients and 258 control subjects also found 
significantly higher concentrations of HbF in both insulin treated Type II and 
Type I diabetic patients.156 Together, these results have prompted independent 
calls for the withdrawal of all glycated haemoglobin methods where fetal 
haemoglobin is a potential interferent in measurement157’158 and hopefully has 
alerted clinicians and equipment manufacturers to the unacceptability of their 
continued use.
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Chapter 5
An Evaluation of Glycaemic Control Limits Using 
the Ames DCA 2000 HbAlc Analyser.
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5.1 Introduction
The introduction of the European consensus guidelines for glycated 
haemoglobin measurement147 not only helped in classifying the glycaemic 
control of individual diabetic patients, but also provided an appealing means of 
comparing the results obtained from different centres when using a variety of 
instrumentation. Indeed, the use of such ‘standard deviation scores’ was 
heralded as ‘a golden opportunity to compare accurately treatment and 
education regimens’.159 However, we have demonstrated that methodological 
difficulties associated with some glycated haemoglobin methods can lead to the 
misclassification of diabetic patients when using these guidelines (see Chapter
4). Since glycated haemoglobin methods do not all suffer from the same 
limitations, we postulated that discrepancies might exist between assays when 
European recommendations are applied. Consequently, this study proposed to 
assess the agreement between different methods when classifying diabetic 
patients using standard deviation cut-offs.
In late 1991 when the study was conceived, a novel method for measuring 
HbAic was undergoing clinical trials before being officially introduced to the 
UK. The Ames (now Bayer) DCA 2000 analyser was a portable instrument 
employing all the reagents for a latex-agglutination immunoassay in a single 
disposable cartridge (see Chapter 3.3.4). It offered the promise of on-site 
measurement of glycated haemoglobin as a consequence of its small size, short 
testing time (9 minutes), and relatively inexpensive cost of the instrument 
(around £2000). The use of a monoclonal antibody to HbAic implied that the 
method was likely to show improved specificity for glycated haemoglobin 
compared to the routinely used Coming electrophoretic HbAj assay. In view of 
their markedly different methods of analysis, it seemed appropriate that these 
two assays should be chosen to assess whether results from different 
instruments could indeed be compared by using European recommendations. 
Therefore, this chapter describes a comparison of the DCA 2000 HbAjc
67
analyser with other measures of glycated haemoglobin with particular regard to 
validating the consensus guidelines.
5.2 Methods
5.2.1 Patients
Reference interval individuals comprised 104 healthy non-diabetic individuals 
(median age 33.5 years, range 15-70) and a male/female ratio of 1:1.
A total of 152 insulin-treated or Type I diabetic patients (median age 43 
years, range 15-84, 73 males, 79 females) attending the routine return diabetic, 
adolescent and pregnant diabetic clinics at Gartnavel General Hospital, 
Glasgow also participated in the study.
5.2.2 Study Design
One hundred and eight patient samples had HbAj measured using an 
electrophoretic method (Ciba Coming Diagnostics Ltd) and HbAjc by the 
DCA 2000 analyser (Bayer Diagnostics Ltd). In 78 of these samples, blood for 
DCA 2000 analysis took the form of a lpL capillary sample measured ‘on-site’ 
over a 6 week period at the clinics described above, while electrophoresis 
HbAj measurements were performed on a venous sample taken by the 
reviewing physician. The remaining 30 samples had both HbAj and HbAjc 
measured on the same venous sample.
Venous results obtained from the DCA 2000 were also compared with 
those obtained from a laboratory based immunoassay HbAjc system, the 
Novoclone (Novo Nordisk Diagnostics Ltd) in a further 44 patient samples.
During the same time period as patient sample measurement, a reference 
range (mean ± 2 standard deviations) for the DCA 2000 assay was established 
using the non-diabetic individuals. A local reference range for the 
electrophoresis HbAj assay had been determined previously.35
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Diabetic patients samples were classified according to European guidelines 
using 2 and 4 SD cut-offs as described in Chapter 4.
5.2.3 Statistical Analysis
Statistical analysis used the McNemar test for paired results and the least 
squares method for correlations.
5.3 Results
5.3.1 Reference Individuals
The non-diabetic reference interval for HbAjc on the DCA 2000 was found to 
be 4.38 to 5.70% (mean 5.04%, SD 0.33%), which was much tighter than that 
of 4.8% to 7.8% previously found with the electrophoretic HbAj method.
5.3.2 Method Comparisons
Haemoglobin A \ c values obtained by the DCA 2000 showed a significant 
correlation with the existing electrophoretic HbAj method (r=0.894, Figure 
5.1). No differences were experienced between using capillary and venous 
blood samples. As expected, the relationship between the 2 HbAjc assays 
(DCA 2000 and Novoclone) was superior (r=0.954, Figure 5.2).
5.3.3 Glycaemic Control Categories
Poor agreement existed between methods when using European guidelines to 
classify patients into good, acceptable and poor glycaemic control (Table 5.1). 
More patients were classified as being in poor control (%2= 30.1, p<0.00001) 
and fewer in good control (%2= 10.3, p=0.0013) when the HbAjc method was 
used instead of HbAj.
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and the Novoclone H bA ic method.
Assay Glycaemic Control Category
Good
(<2SD from non­
diabetic mean)
Acceptable
(2-4SD)
Poor
(>4SD)
H b A i 25 33 50
(Electrophoresis) (23%) (31%) (46%)
H b A ic 13* 13 82**
(DCA 2000) (12%) (12%) (76%)
*p=0.0013 and **p<0.00001 compared with HbAi by 
elecrophoresis.
Table 5.1 Glycaemic control categories for 108 diabetic 
patients classified using HbAi and H bA ic.
69
5.4 Discussion
This study has shown that, when using European recommendations, HbAjc 
measured by an immunoassay technique can classify diabetic patients 
differently to the electrophoretic HbAj assay. Sixty four percent more patients 
were classified as poorly controlled using HbAjc compared with HbAp 
Likewise, 48% fewer patients were in good control with the HbAjc assay.
Reasons for the discrepancy between the two methods centres on the fact 
that the non-diabetic SD for the DCA 2000 is much smaller than that for 
electrophoresis (0.33% vs. 0.75%), and so the >4SD definition of poor control 
is much tighter for this HbAjc assay, perhaps as a result of its greater 
specificity. Whatever the reason, the 2 and 4SD categories for the 
electrophoretic assay equate to nearer 5 and 8SD when using this HbAjc assay 
with the locally derived reference interval.
It seems unlikely that the findings in this study are peculiar to the 
indigenous West of Scotland non-diabetic population since the DCA 2000 
manufacturers quote a reference range from 263 individuals which is almost 
identical (mean HbAjc 5.1%, SD 0.3%). It also seems improbable that the new 
DCA 2000 is reporting inaccurate patient results since they largely agreed with 
those obtained by the Novoclone method. Indeed, the DCA 2000 instrument 
itself proved to be a useful tool for use at diabetic clinics, especially since it 
only required the minimum of technical skill to produce acceptable results. The 
only difficulty experienced was the simple capacity of the system. With a 
maximum throughput of six samples per hour it would be necessary to have 
more than one instrument in use if a large number of patients were to be tested.
In conclusion, we found that the use of different glycated haemoglobin 
methods can lead to a discrepant classification of glycaemic control in diabetic 
patients which may relate to the specificity of the assay used and the nature of 
the analyte being measured.
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Primarily because of the presentation and publication of the findings in this 
study, the original European guidelines were changed so that the SD cut-offs 
were more attainable when using HbAjc assays.160 They now recommended 
that good glycaemic control be defined as a HbAj or HbAjc less that 3SD’s 
from the non-diabetic mean value, acceptable control (now renamed 
borderline) be between 3 and 5SD, and poor control be outwith 5SD.89 These 
glycaemic control limits continued to be applicable to both Type I and Type II 
diabetic patients.
Chapter 6
The Classification of Glycaemic Control in 
Diabetes Mellitus using HbAj and HbAjc.
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6.1 Introduction
In September 1993, one of the most influential studies in the history of diabetes 
reported. The results of the Diabetes Control and Complications Trial (DCCT) 
showed an impressive reduction in microvascular complications in an 
intensively treated group of Type I patients compared to those who were 
treated conventionally.25 In this study, the cornerstone of treatment evaluation 
was the measurement of glycated haemoglobin in the form of HbAjc. Thus, 
the study results not only reinforced the need for good glycaemic control but 
also focused minds on the importance of an accurate and standardised means of 
assessing glucose control.
We previously found that the use of different glycated haemoglobin 
methods could lead to discrepancies in the classification of glycaemic control 
when using European consensus guidelines (see Chapter 5). However, some 
consequences of the study itself also raised further questions. Firstly, it was not 
possible to establish whether the discrepancies found were because two 
markedly different methods were used (electrophoresis and immunoassay) or if 
it was solely because one assay measured HbAj while the other measured 
HbAjc. Secondly, although the study used locally derived reference intervals, 
they were not established using the same individuals at the same time which 
may have had a minor influence on our findings. Lastly, the change in 
guideline SD cut-offs in response to our findings (from 2 and 4 SD’s to 3 and
5) meant the results of the original study may no longer have been applicable. 
During this period, the consequences of misclassifying a patient’s glycaemic 
control were highlighted by the DCCT and helped cement the need for a further 
study to clarify the points raised. This chapter addresses these points.
The first aim of the study was to determine if the discrepant classification 
of diabetic patients remained when the new cut-offs of 3 and 5 SD were 
applied and the same non-diabetic individuals were used to construct reference 
intervals for the different assays. A second aim was to try and establish if,
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when employing the new guidelines, HbAj fundamentally classified patients 
differently to HbAjc even when the same high performance liquid 
chromatography instrument of analysis was used. If this proved to be the case 
then the interchangeable use of HbAi and HbAic for the measurement of 
glycaemic control would require reappraisal.
6.2 Methods
6.2.1 Patients
The reference range sample consisted of 106 non-diabetic individuals (42 male, 
64 female, median age 36 years (range 16 to 82)) comprising hospital staff and 
families. Two hundred and eight consecutive patients (114 male, 94 female, 90 
insulin treated, 118 non-insulin treated, median age 60 years (range 13 to 94)) 
attending the diabetic out-patient clinic at Gartnavel General Hospital,
Glasgow also participated in the study.
6.2.2 Study Design
Two methods of glycated haemoglobin analysis were used: HbAj and HbAjc 
were measured individually by high performance liquid chromatography 
(HPLC) (Hi-AutoAlc, model 8121, Biomen UK Ltd); HbAi was additionally 
measured by an electrophoretic method (Ciba Coming Diagnostics Ltd).
A locally derived non-diabetic reference range (mean ± 2 standard 
deviations) was established for the HPLC methods (HbAi and HbAic) and for 
the electrophoretic method. During the same time period, blood from the 
diabetic patients was collected for the same range of glycated haemoglobin 
analyses.
Diabetic patient samples were categorised according to European IDDM 
and NIDDM guidelines. Good glycaemic control was defined as a HbAi or 
HbAic value less than 3 standard deviations from a method’s non-diabetic
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population mean. Borderline control was between 3 and 5 standard deviations 
and poor control was above these limits.89
6.2.3 Statistical Analysis
Statistical analysis used the McNemar test for paired samples and the chi- 
squared test for unpaired proportions. The Gaussian distribution of the 
reference samples was verified using Kolmogorov-Smimov one way analysis. 
Correlations used the least squares method.
6.3 Results
6.3.1 Reference Individuals
Table 6.1 shows the results of glycated haemoglobin measurements obtained 
from the reference population for each analysis with their respective good, 
borderline and poor control limits. The spread (standard deviation) of each 
assay’s reference values are also expressed as a percentage of the method mean 
(sample coefficient of variation). Results for the electrophoretic HbAj method 
are consistent with those obtained previously in Chapter 5.
6.3.2 Diabetic Patients
Figure 6.1 demonstrates good correlation between the two HbAj assays and 
HbAjc. HbAi by electrophoresis also correlated with HbAi by HPLC 
(y=0.90x +1.61, r=0.888).
Despite the agreement between methods, Table 6.2 shows significantly 
fewer patients classified in good control and more as poorly controlled with 
HbAic (HPLC) compared to both HbAi assays (both p<0.0006). This was true 
for both insulin treated and non-insulin treated patients (no significant 
difference). The clinic patient median HbAic (HPLC) value was 
proportionately higher than HbAi (both by HPLC and electrophoresis) when
HbAic (%) 
(HPLC)
HbAi (%) 
(HPLC)
HbAi (%)
(Electrophoresis)
Reference Population Statistics
Mean 4.02 5.88 6.30
Standard
Deviation
0.28 0.46 0.75
Coefficient 
of variation
7.1% 7.8% 11.9%
Derived Glycaemic Control Categories
Good
(<3 standard 
deviations)
<4.87 <7.25 <8.55
Borderline
(3-5
standard
deviations)
4.87-5.44 7.25-8.17 8.55-10.05
Poor
(>5 standard 
deviations)
>5.44 >8.17 >10.05
Table 6.1 Reference population statistics and 
derived glycaemic control categories (n=106)
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HbAic
(HPLC)
HbAi
(HPLC)
HbAi
(Electrophoresis)
Diabetic Patient Statistics
Median 
value (%)
6.3 8 . 6 9.35
Standard
Deviations
from
reference
mean
8 . 0 5.9 4.1
% above 
reference 
mean value
56.7% 46.2% 48.4%
Glycaemic Control Category
Good
Control
25
(1 2 %)
39*
(18.8%)
63**
(30.3%)
Borderline
Control
26
(12.5%)
39*
(18.8%)
y |  ^  ^
(34.1%)
Poor
Control
157
(75.5%)
130**
(62.4%)
7 4 **
(35.6%)
* p= 0.0005 and **p<0.00001 compared with HbAic (HPLC)
Table 6.2 Diabetic patient statistics and glycaemic 
control according to European IDDM 
guidelines (n=208)
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compared to the reference population. Constituents of HbAi other than HbAjc 
i.e. HbAja i, HbAja2  and HbAj^, were estimated by subtracting the HbAjc 
value from HbAj. The median diabetic patient value for this was 2.3% which 
represented a 24% increase above the non-diabetic mean of 1.8 6 %.
Figure 6.2 demonstrates why more patients were classified as poorly controlled 
using HbAjc measurement. The distribution of diabetic patient samples using 
HbAic (HPLC), HbAi (HPLC) and HbAi (electrophoresis) is shown as a 
function of the standard deviations from their respective method means.
6.4 Discussion
The results of the Diabetes Control and Complications Trial have provided the 
best objective guide for desirable glycaemic control limits to prevent 
microvascular complications in Type I diabetes. In that study, the median 
HbAic of the intensively treated patients was 4 standard deviations from the 
mean non-diabetic value whilst the conventionally treated group was 8 
standard deviations from the mean.25 In the study described in this chapter, the 
median diabetic value was 4.1 standard deviations from the non-diabetic mean 
using electrophoretically measured HbAi, 8-0 using HbAic (by HPLC) and 5.9 
by HbAi using HPLC. Thus, depending on the method of glycated 
haemoglobin used, our same diabetic clinic patients could be described as 
equivalent to either the intensively treated group, the conventionally treated 
group or approximately midway between. Although our study included non­
insulin dependent patients, it has been suggested that the results of the DCCT 
are likely to be equally applicable to this group with diabetes.27
In October 1993, submission of samples to the United Kingdom National 
External Quality Assessment Scheme (UK NEQAS) reported 4 different 
instruments for HbAi measurement (with the Coming electrophoresis being 
the commonest) together with 8 instruments for HbAic analysis (with HPLC
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the commonest method). This present study has clearly demonstrated that there 
is considerable discrepancy in the classification of glycaemic control when 
comparing the electophoretic HbAj method with HbAjc HPLC analysis.
Using revised European guidelines, 36% of our patients were poorly controlled 
(>5 SD’s) using electrophoresis compared to 76% using HbAjc measured by 
HPLC. This is consistent with our previous findings in Chapter 5 when 
comparing electrophoretically measured HbAi with HbAjc measured by an 
agglutination inhibition immunoassay method.
Publication of the DCCT results emphasised the need for consistency 
between centres regarding the measurement of glycated haemoglobin.26 One of 
the objectives of providing guidelines based on SD’s was to allow diabetic 
units to compare data and perform useful audit. Since our routine assay at the 
time of this study was HbAj by electrophoresis (where more patients appear to 
have good control) we will always have erroneously appeared to have patients 
with better glycaemic control in comparison to a centre using a HbAjc assay!
This discrepancy is not confined to only the electrophoretic HbAj assay. 
This study has also shown that a marked disparity between HbAj and HbAjc 
categorisation remained even when patient specimens were measured by HPLC 
using the same instrument, time of analysis and reference range samples. 
Significantly more patients had poor control as assessed by HbAjc than by 
HbAi (76% vs. 62%). The reasons for this appear twofold. Firstly, the spread 
(standard deviation) of the non-diabetic HbAi reference population results was 
relatively greater than HbAic (7.8% vs. 7.1% of the mean reference value). 
Thus more diabetic samples fell within 3 and 5 standard deviations by using 
HbAi rather than HbAic. Secondly, in comparison to non-diabetic values, 
patient HbAic values were relatively higher than HbAi (median value 57% vs. 
46% greater than reference mean). The implication is that this is due to 
glycated analytes of HbAi other than HbAic (HbAiai, HbAi 32  and HbAib) 
rising less rapidly than HbAic itself.
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There remained a significant difference in the classification of glucose 
control between the two HbAj methods: 62% of patients were poorly 
controlled using HPLC and 36% by electrophoresis. This was due to the 
electrophoretic assay exhibiting a relatively higher reference range standard 
deviation (11.9% of the mean vs. 7.8%). This disparity is likely to be due in 
part to the fact that, unlike the chosen HPLC method, both glycated and non­
glycated fetal haemoglobin comigrates with HbA\ in this electrophoretic assay 
and so is included in the HbAj result.98 Chapter 4 showed that this may not 
only lead to spuriously raised HbAj values in some patients but an increase in 
the imprecision (and therefore reference range) of the assay as a whole.
In conclusion, this study has found marked differences in the classification 
of glycaemic control in diabetic patients when using HbAi measurement rather 
than HbAic. In relation to the Diabetes Control and Complications Trial, this 
inconsistency may have considerable consequences for the long term well­
being of diabetic patients and may also influence the allocation of resources 
towards their treatment. Therefore, these findings reinforce the need for more 
standardisation in the methods used for the measurement of glycated 
haemoglobin. The adoption of a standardised HbAic would allow the 
development of clear guidelines for clinicians based on both recent and 
subsequent complications trials- a sentiment echoed by representatives from 
the British Diabetic Association in response to the publication of this study.87
Much of the correspondence which followed this study described 
alternative approaches which may be taken to address the guideline 
shortcomings. The author’s suggestion, 161 which was also common to a 
number of communications, 162’163 was to express patient glycated haemoglobin 
results as multiples of the non-diabetic mean value (MoM) in a situation 
analogous to that already used in Down’s syndrome and neural tube defect 
screening. This proposal was based on the fact that assay imprecision only 
affects the spread of results, it does not affect either the mean glycated
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haemoglobin value of a reference interval population or the median value of a 
diabetic clinic population. Thus, by eschewing the use of standard deviations, 
the effect of variations in glycated haemoglobin assay imprecision would be 
minimised.
Applying this proposal to the study in this chapter, the median diabetic 
HbAi value using HPLC was 1.46MoM i.e. 46% greater than the non-diabetic 
mean value, which is similar to the value of 1.48MoM found when using 
electrophoresis. However, this method of comparison still leads to 
discrepancies when comparing HbAi with HbAjc. Presumably because 
HbAic concentrations rise faster in diabetic patients than HbAi, the median 
HbAic value implied poorer glycaemic control at 1.57MoM. As a guide, the 
intensively treated group in the Diabetes Control and Complications Trial had a 
median HbAic value of approximately 1.40MoM while that of the 
conventionally treated group was I.8 OM0 M.
Thus, whilst comparisons of either 2 HbAi or 2 HbAic methods by 
MoM’s may be valid, the situation remains that comparing HbAi with HbAic 
can be problematic.
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Chapter 7
The Effects of Ageing on Glycation 
and the Interpretation of Glycaemic Control 
in Type 2 Diabetes.
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7.1 Introduction
We have shown some of the limitations that exist when attempting to classify 
glycaemic control in diabetic patients using glycated haemoglobin, primarily as 
a result of lack of standardisation in measurement (see Chapters 4 to 6 ). One of 
the proposed advantages of the serum fructosamine assay was that commercial 
quality control sera could be used to standardise this method of glycaemic 
control assessment and thus ensure comparable results from different 
laboratories.47 The reasons as to why serum fructosamine has not therefore 
become generally accepted in preference to glycated haemoglobin are probably 
diverse but are likely to include its perceived lack of specificity for protein 
glycation164 and, most tellingly, its lack of consistent correlation with glycated 
haemoglobin measurements.40’42’43 Therefore glycated haemoglobin remains 
the most popular measure of prior glucose control, despite the inability to 
effectively compare results between centres.
The attempts to compare glycated haemoglobin results from different 
assays include the European guidelines and the ‘multiples of the mean’ 
proposal outlined in Chapter 6 . Both approaches put great emphasis on the 
establishment of an accurate assay reference interval. Since locally derived 
reference intervals are traditionally determined using young, healthy hospital 
staff, any age variation in non-diabetic glycated haemoglobin may render 
comparison to older diabetic patients inappropriate. This study aimed to 
determine if non-diabetic glycated haemoglobin and fructosamine values vary 
with the age of the subjects chosen.
7.2 Methods
7.2.1 Patients
Two hundred and thirty two non-diabetic individuals (95 male, 137 female, 
median age 47, range 16-74, fasting plasma glucose < 6.4 mmol/L 165>166) took
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part in the study. These subjects comprised hospital staff and individuals 
attending a clinic for lipid assessment. The clinic patients were subsequently 
confirmed as having repeated fasting glucose values less than 6.4 mmol/L.
One hundred and twenty eight Type 2 diabetic patients (median age 63, 
range 50-75, median HbAjc 6.4%) attending the Diabetic Clinic, Gartnavel 
General Hospital, Glasgow also participated.
7.2.2 Study Design
HbAic was measured by HPLC (Hi-AutoAlc, model 8121, Biomen UK Ltd) 
in all non-diabetic subjects. In a subgroup of 126 of these individuals (54 male, 
72 female, median age 57 years, range 23-74), serum fructosamine 
(Fructosamine Plus, Roche Diagnostics), serum albumin and body mass index 
(BMI) were also measured.
The diabetic patients were classified according to amended European 
guidelines into good (HbAic value <3 SD from non-diabetic mean value), 
borderline (3-5SD) and poor (>5SD) glycaemic control using reference 
intervals derived from both an age matched (n=101, median age 63 years, 
range 50-75) and a younger population (n=108, median age 37 years, range 25- 
50).
Patients were also classified using ‘multiples of the mean’ (MoM) where 
the median clinic HbAjc value is expressed as a proportion of the non-diabetic 
mean value (see Chapter 6.4). Both the mean non-diabetic values from the age 
matched subjects and younger subjects were used.
7.2.3 Statistical Analysis
Statistical analysis used the McNemar test for paired samples. Correlation 
coefficients were calculated by the least squares method. Regression slopes and 
intercepts were compared using t-tests.
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7.3 Results
7.3.1 HbA] Fructosamine and Age
A linear relationship between HbAjc and age was obtained in the 232 non­
diabetic subjects (r=0.49, pO.OOOl). There was no significant difference 
between males and females in the regression line slope (0.0108 ± 0.00262 
SEM vs. 0.0132 ± 0.00178 respectively) or intercept (3.631 ± 0.122 vs. 3.538 ± 
0.090 respectively). Mean HbAjc rose from 3.82% to 4.44% between the ages 
of 20 and 70 (Figure 7.1).
In the subgroup of 126 non-diabetic subjects, the rise in HbAjc with age 
(r=0.49) was not reflected by similar increases in serum fructosamine 
concentrations (Figure 7.2) or fasting glucose measurements (Figure 7.3) 
(r=0.07, r=0.009 respectively, p=NS). Serum albumin concentrations (median 
44g/L, range 35-52) and body mass indexes (median 25.5kg/m2, range 18.2- 
35.2) showed no linear relationship to age in this sample (p>0.05). The 
fructosamine/albumin ratio was also unrelated to age (p>0.05).
7.3.2 Glycaemic Control Classification
As a consequence of greater HbAjc values in elderly non-diabetic individuals, 
the reference interval derived from non-diabetic subjects age matched to the 
Type 2 patients was higher (mean HbAjc 4.31%, SD 0.37%) than that of the 
younger age group (mean 4.03%, SD 0.30%). Therefore, according to 
European guidelines, fewer diabetic patients were in good control (14% vs. 
25%) and more in poor control (73% vs. 53%) when the younger reference 
interval was used (both p<0.05 by McNemar tests, Table 7.1).
When using ‘multiples of the mean’, the same diabetic patients were 
1.48MoM using the age matched reference interval and 1.59MoM using that 
derived from younger subjects.
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Non-Diabetic
Controls
Glycaemic Control Category
Good
(<3SD from non­
diabetic mean)
Acceptable
(3-5SD)
Poor
(>5SD)
Age Matched 32 28 68
(50-75yrs) (25%) (22%) (53%)
Younger 18* 17
(25-50yrs) (14%) (13%) (73%)
*p<0.05 and **p<0.01 vs. age matched controls.
Table 7.1 Classification of glycaemic control in 126
type 2 diabetic patients using age matched and 
younger controls.
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7.4 Discussion
This study has shown that non-diabetic HbAjc values increase with subject age 
which in turn may affect the assessment of glycaemic control in diabetic 
patients. By using a reference interval derived from young individuals, more 
Type 2 diabetic patients appeared in poorer glycaemic control when using 
European guidelines than if an age matched non-diabetic population was used 
(73% vs. 53%). The use of ‘multiples of the mean’ as a method of comparing 
glycated haemoglobin values from different assays was also affected. Again, 
the younger controls made the diabetic patients appear more poorly controlled. 
Indeed, the discrepancy (1.59 vs. 1.48MoM) was similar in magnitude to that 
found when comparing HbAic with HbAj in Chapter 6 . Therefore, to take 
account of these problems, age related reference ranges may need to be used 
when interpreting HbAjc results.
This report has also shown clear differences when comparing HbAjc with 
fructosamine in non-diabetic subjects of varying ages. Some of this 
inconsistency can be explained by the fact that HbAjc reflects glycaemic 
control over the preceding 6 -8  weeks compared with 1-3 weeks for 
fructosamine. 14’71 Fructosamine measurements can also be influenced by other 
factors such as the serum albumin concentration and body mass index (BMI) of 
the patient (see Chapter 2.3). However, despite the subjects in this study having 
similar serum albumin concentrations / BMI’s and presumably being in stable 
glucose control, HbAjc values increased with subject age whereas 
fructosamine did not.
The reasons for this discrepancy remain speculative. Like other 
studies, 167’168 this investigation showed little change in fasting plasma glucose 
with increasing age which, at first glance, would appear to indicate that serum 
fructosamine is the more representative marker of glucose control. However, 
this deduction does not take account of the larger glycaemic excursions which 
are likely to occur post-prandially in elderly individuals. 167 As such, it remains
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difficult to establish whether it is HbAjc or fructosamine that is most 
accurately reflecting glycaemia in these subjects.
It has been suggested that degrees of glucose intolerance may explain only 
one third of the variance of glycated haemoglobin levels in non-diabetic 
subjects. 169’170 Thus, another possible explanation for our HbAjc findings 
would be if a factor which changes with increasing subject age also affected 
HbAjc values. For example, if red blood cell lifespan was longer in elderly 
subjects, this would allow greater glycation of their haemoglobin. In fact, it 
would seem that erythrocyte lifespan paradoxically shortens with increasing 
subject age. 171
Our HbAjc results are consistent with those of a previous more limited 
study of 48 non-diabetic individuals where values were found to be higher in 
elderly patients172 although, curiously, this was not the case in another study 
where total glycated haemoglobin was measured instead of HbAjc . 168 Our 
fructosamine data are also in agreement with a European fructosamine 
workshop report which concluded that, above 16 years, age had little effect on 
serum fructosamine concentrations. 119 However, no previous study has 
evaluated both fructosamine and HbAjc in the same subjects. These age 
differences, if applicable to diabetic patients, may be an additional reason for 
the discrepancy found when comparing HbAjc with fructosamine.
These findings are of clinical relevance because, in contrast to 
fructosamine, HbAjc reference intervals are likely to be influenced by the age 
of the subjects chosen and so may partly explain the diversity of locally derived 
reference intervals quoted when using the same glycated haemoglobin 
instrument. 173 In addition, if, as our data suggest, the glycated haemoglobin 
values from elderly subjects are closer to those of diabetic patients than 
younger individuals are, then it may also account for the finding that HbAjc is 
a better screening test for diabetes in middle aged rather than elderly people. 19
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It would seem appropriate that clinicians should aim for their diabetic 
patients to have comparisons in glycated haemoglobin values made to those of 
their non-diabetic chronological peers. To this end, age related reference 
intervals may be required for glycated haemoglobin measurements to facilitate 
more accurate glycaemic control targets for patients and for better auditing of a 
clinic performance.
Chapter 8
Parallel Measurements of 
Fructosamine and Glycated Haemoglobin 
in Type 2 Diabetic Patients.
87
8.1 Introduction
As eluded to in Chapter 1.2.2, cross-sectional comparisons of serum 
fructosamine and glycated haemoglobin have revealed inconsistencies between 
the two measures. Some of the reasons for the discrepancies have already been 
described in Chapter 2.3, and include the effect of serum protein concentrations 
and obesity on the fructosamine assay. The studies in Chapters 4 and 7 have 
also demonstrated that comparisons may be influenced by both the choice of 
glycated haemoglobin analysis used and by age related changes in HbAjc 
measurements.
Notwithstanding these causes of disagreement, it is likely that the major 
reason for disparity between the two assays is that fructosamine gives an 
indication of glycaemia over the preceding 1-3 weeks71 while that of glycated 
haemoglobin is over a period of at least the prior 6 -8  weeks. 14 In view of the 
different time periods they represent we postulated that the relationship 
between fructosamine and glycated haemoglobin may vary depending on 
whether glycaemic control was stable or undergoing change. In addition, if 
changes in serum fructosamine were to precede those of HbAj, then the 
fructosamine/HbA \ ratio could be useful as a prospective indicator of trends in 
HbAj in diabetic patients. Therefore, to resolve these issues, this study aimed 
to assess longitudinal changes in HbAj and fructosamine concentrations by 
observing them in a group of Type 2 diabetic patients immediately following 
treatment changes. Haemoglobin A \  rather than HbAjc was chosen as the 
form of glycated haemoglobin measurement because the study was performed 
at a time when this was the commonest means of measuring glycated 
haemoglobin before HbAjc had gained widespread use in clinical practice.
8.2 Methods
8.2.1 Patients
Fourteen patients with Type 2 diabetes (9 males, 5 females, median age 56 
years, range 36-72) were recruited from the Diabetic Outpatient Clinic. Six 
patients were newly diagnosed and eight were known diabetic patients with 
symptomatic hyperglycaemia over 4-6 weeks prior to attendance but with no 
evidence of intercurrent illness. All were free from diabetic complications and 
had normal renal function.
8.2.2 Study Design
In order to improve glycaemic control during the period of study, 2 patients 
were treated by dietary measures alone, 5 by diet plus and oral hypoglycaemic 
agents and a further 7 were commenced on insulin treatment, depending on 
previous diabetic status and treatment. Out of the 14 patients, 10 were followed 
for 16 weeks, 3 for 12 weeks and one patient terminated the study at week 8 . 
Two patients had missing values for fasting blood glucose between weeks 2-4 
of the study.
Whole blood was obtained for HbAj measurement by electrophoresis 
(Ciba Coming Ltd, UK) and the remainder centrifuged for the analysis of 
plasma glucose, serum fructosamine and serum albumin. Serum fructosamine 
was measured using the original fructosamine kit (Roche Diagnostica, UK) as 
described in Chapter 1.4.2. Fasting blood glucose was measured on a Beckman 
II glucose analyser (Beckman Ltd) and serum albumin (reference interval 35-45 
g/L) on a SMAC II multi-channel analyser (Technicon Corporation, 
Basingstoke, UK).
89
8.2.3 Statistical Analysis
Statistical analysis was performed using the Student's t-test and Mann-Whitney 
U tests where appropriate. The correlation coefficients were calculated by the 
least squares method. Values were expressed as mean + SD unless otherwise 
stated.
8.3 Results
8.3.1 Changes in Glycaemia
Figure 8.1 shows the changes in fructosamine, HbAj and fasting plasma 
glucose during the period of study. During the study there was no change in 
serum albumin concentration (41.6 + 3.9 g/L initially and 43.1 + 2.5 g/L at 
week 16). Mean fasting plasma glucose concentration fell significantly in each 
of the first 2 weeks and remained unchanged thereafter. There was a decrease 
in HbAi after 1 week and at 4 weeks and this continued to fall until 16 weeks. 
Fructosamine concentration decreased at 1, 2 and 4 weeks and remained 
unchanged thereafter.
8.3.2 Comparison of Fructosamine and HbAi
The correlation between serum fructosamine and HbAj for all patients 
assessed in a cross-sectional manner at each of the eight visits over the 16 
week period varied from r= 0.13 to r= 0.87 (Table 8.1) but only reached 
statistical significance (p<0.05) at week 12 (p=0.018) and week 16 (p=0.001). 
When the concentrations of fructosamine and HbAj were compared in 
individual patients over the 16 week period of study, significant correlations 
were found in 8 out of 14 patients (Table 8.2).
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Week Correlation between Fructosamine and HbAi
r P
0 0.55 0.06
1 0.43 0.14
2 0.23 0.36
4 0.13 0 . 6 6
6 0.39 0 . 2 1
8 0 . 2 1 0.47
1 2 0.60 0.018
16 0.87 0.00092
Table 8.1 Correlation between HbAi and fructosamine at 
different time points in the group (n=14).
Patient Number Correlation between Fructosamine and HbAj
r P
1 0.920 0.001
2 0.911 0.001
3 0.797 0.031
4 0.920 0.001
5 0.789 0.019
6 0.553 0.005
7 0.850 0.015
8 0.783 0.021
9 0.326 0.475
10 0.140 0.101
11 0.778 0.120
12 0.632 0.090
13 0.048 0.074
14 -0.121 0.818
Table 8.2 The relationship between serum fructosamine and 
HbAi in individual patients during 16 week 
monitoring period.
90
8.3.3 Fructosamine/ HbA| Ratio
The fructosamine/ HbAj ratio at a single time-point correlated with the change 
which occurred in the HbAi value the following month (r=0.54, p<0.001, 
Figure 8.2).
8.4 Discussion
There remains uncertainty as to the interpretation of the fructosamine 
concentrations in the diabetic clinic situation. The use of serum fructosamine 
as an indicator of glycaemia has been at least partly hindered by a lack of 
consistency found in cross-sectional comparisons with glycated 
haemoglobin.34-43 Rather than dismiss fructosamine on this basis, this study has 
addressed the possible benefits that parallel measurement of fructosamine and 
HbAj may bring.
Few studies have evaluated longitudinal changes in serum fructosamine.4,41 
Those that have are either limited by sampling at clinic visits 5 months apart41 
or because detailed comparisons were not made with glycated haemoglobin 4 
Thus, the bulk of present data on the interrelationships between fructosamine 
and HbA] largely depend on cross-sectional analysis of groups of patients at a 
single time point.
The results presented in this chapter have shown that no one relationship 
exists between fructosamine and glycated haemoglobin: even amongst the 
same group of diabetic patients the correlation between fructosamine and 
HbAi values varied markedly (from r= 0.87 to r= 0.13) depending on whether 
the subjects were in stable or changing glycaemia. One of the best correlations 
occurred at week 0 when glycaemic control was poor but presumably stable, 
yet took 12 weeks following an acute change in glycaemia before becoming 
concordant again. This was because HbAi showed a sustained fall throughout 
the study period whereas fructosamine showed its most significant falls in the 
first month. Presumably this was a consequence of a long half-life protein
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Figure 8.2 The correlation of the fructosamine/HbAl ratio
with change in HbAi concentration over the
following month.
91
(HbAi) requiring a longer time to reach a new equilibrium than most proteins 
found in serum. These results are consistent with those of a previous study 
which showed fructosamine correlating with HbAj at admission to a diabetic 
day care unit (r=0.75), but not 2 weeks after discharge (r=0.29).153
It has previously been suggested that the parallel measurement of the two 
variables may provide a better insight into a patient's glycaemic control than 
the measurement of either HbAj or fructosamine alone.40 The findings in this 
study have confirmed this by demonstrating that the fructosamine/ HbAj ratio 
can predict the changes in HbAj which occur at a patient's subsequent visit to 
the clinic. Thus, simultaneous measurement gives the clinician a patient’s 
HbAj value together with an indication of whether it is improving or 
worsening. This may prove valuable if found to be applicable to pregnant 
diabetic patients or those on oral hypoglycaemics who are approaching the 
need for insulin treatment. From the findings in Chapter 4, it seems probable 
that measuring HbAic rather than HbAj will provide similar benefits.
In conclusion, this study has found that in Type 2 diabetic patients the 
different time period of glycaemia reflected by fructosamine and HbAi 1S a 
major contributor to discrepancies found when comparing the two methods. 
However, knowledge of this fact means that simultaneous measurement of 
fructosamine and HbAi can give valuable information on future trends in 
HbAi values.
Since the publication of this study, no further studies have reported on the 
longitudinal changes found when measuring fructosamine and glycated 
haemoglobin. The use of the fructosamine/ HbAi ratio has not become 
widespread, but at least one manufacturer of equipment and reagents 
(Boehringer Mannheim) advocates its use and have adapted their instruments 
for simultaneous measurement of the two analytes.
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Chapter 9
The Effects of Variations in Haematocrit, 
Mean Cell Volume and Red Blood Cell Count 
on Reagent Strip Tests for Glucose.
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9.1 Introduction
Throughout the 1980’s measurement of blood glucose, other than that for 
diagnosis, showed a steady move away from laboratories into the hands of 
diabetic patients and health care workers. The use of glucose test strips and 
meters became commonplace not only amongst diabetic patients in the 
community but also for the monitoring of acutely ill hospital patients. The 
latter was illustrated by the fact that in 1994 over three ward glucose 
measurements were being performed in the author’s hospital unit for every 
sample sent to the biochemistry laboratory.
Use of test strips in a hospital setting requires that they can give accurate 
results under a wide variety of physiological conditions. This and subsequent 
chapters in the thesis describe limitations in the performance of several popular 
glucose test strips and meters when a range of pathological specimens are used.
By 1992, in vitro variations in sample haematocrit had consistently been 
shown to be a source of error in several of the most commonly used reagent 
strip tests for glucose (see Chapter 2.4.3).137-140 In general, blood glucose 
measurements by these methods usually varied inversely with increasing 
sample haematocrit. Thus, patients with abnormally low haematocrits had 
spuriously high test strip measurements and vice versa.
The author’s recognition of this problem was stimulated by the case of a 72 
year old man who had been admitted to the hospital’s general medical wards 
with an exacerbation of chronic obstructive airways disease. The biochemistry 
laboratory was contacted because ‘Glucostix’ test strip and meter blood 
glucose measurements were consistently giving measurements of around 8 
mmol/L while simultaneous venous samples sent to the laboratory were in 
excess of 20 mmol/L. Serum osmolality measurements indicated that the 
patient was likely to be truly hyperglycaemic. It transpired that the patient had a 
haematocrit value of 65% because of secondary polycythaemia and that this 
was causing spurious reductions in test strip glucose measurements.
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Despite cases such as this, recognition of the influence of haematocrit 
amongst clinicians and nursing staff was not widely appreciated and many 
glucose strip manufacturers had not yet developed products which addressed 
this shortcoming. The study in this chapter was conducted around this time to 
assess the effect of other haematological indices on glucose test strip 
measurement.
The haematocrit of a sample is not a single entity, but is dependent on two 
other haematological parameters, namely, the red blood cell count (RBC) and 
the mean cell volume (MCV) of a sample. They are related as follows:
Haematocrit = RBC x MCV
Consequently, patients with variable MCV may have the same haematocrit 
but widely differing red cell counts (Figure 9.1). The corollary of this is that 
studies which use normal subjects (presumably with similar MCVs) make it 
impossible to distinguish if the test strip error is due to haematocrit variations 
per se or actually due to changes in the number of red cells. Therefore, the 
study in this chapter aimed to ascertain how variations in haematocrit, RBC 
and MCV affect strip glucose measurement in 3 commonly used glucose 
meters.
9.2 Methods
9.2.1 Patients
Samples were obtained from 3 groups, each comprising of 3 non-diabetic 
males: The first group consisted of subjects with normal mean cell volumes 
(mean 88.9[range 88.2-89.7]fL), while 2 further groups comprised individuals 
with low (mean 70.4[range 67.5-72.5]fL) and high (mean 112.6[range 109.8- 
115.9]fL) MCVs.
Red Cells Test Strip Surface
Figure 9.1 Stylised representation o f 2 blood samples
with the same haematocrit, but differing red 
cell counts.
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9.2.2 Study Design
Blood was collected in K2 EDTA and had haematocrit, RBC and MCV 
measured using a Coulter S+4 analyser (Coulter Corp, Harpenden, 
Herfordshire, UK) before spiking with 10% glucose to produce samples with a 
mean plasma glucose of 12.1 mmol/L. The reference interval for MCV using 
this analyser was 80-100fL.
The whole blood was centrifuged and homologous plasma either removed 
or added to produce samples with haematocrits from 20% to 60% in 10% 
increments.
Whole blood glucose for each sample was measured using the Glucometer 
Gx, the Reflolux IIM and the ExacTech credit card sensor. Plasma glucose was 
measured on a ‘Dimension’ analyser.
All whole blood and plasma samples for each subject were analysed within 
30 minutes of one another and all measurements accounted for the dilutional 
effect of spiking.
9.2.3 Statistical Analysis
Simple and multiple regression was performed by the least squares method and 
comparisons of samples used the Mann-Whitney U test.
9.3 Results
9.3.1 Haematocrit and Glucose Meter Measurement
Glucose measurements were related to haematocrit in all three meters. Every 
10% increase in haematocrit led to Reflolux glucose measurements falling by 
6% (r= -0.86), ExacTech by 15% (r= -0.87) and Glucometer by 19% (r= -0.91).
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9.3.2 Red Blood Cell Count and Glucose Meter Measurement
The variation of glucose strip accuracy (as a percentage of the plasma glucose 
measurement) with haematocrit was not significantly different between MCV 
groups in any of the meters.
Consequently, glucose strip accuracy correlated less well with red blood 
cell count than with haematocrit (r= -0.83 vs. r= -0.86 (Reflolux), r= -0.73 vs. 
-0.87 (ExacTech) and r= -0.74 vs. -0.91 (Glucometer)). Figure 9.2 
demonstrates this for the Glucometer Gx. It shows the accuracy of this meter at 
a given red cell count differing according to MCV, but variations of accuracy 
with haematocrit to be independent of red cell size i.e. so long as the same area 
of a test strip is covered by red cells, identical glucose results will be obtained, 
regardless of whether this area is composed of a large number of small cells or 
a small number of large cells.
Multiple regression showed RBC measurement did not add significantly to 
the relationship between glucose strip error and haematocrit.
9.4 Discussion
Monitoring blood glucose in a hospital environment may commonly include 
patients with low or high haematocrits and low or high mean cell volumes. 
Low haematocrits can often be found in patients with blood loss or 
haematological disorders while high haematocrits may occur in polycythaemic 
and dehydrated subjects. Discrepancies between haematocrit and red cell count 
can occur in patients with anaemia because although all types exhibit a low 
haematocrit they may have either low, normal or high mean cell volumes 
depending on the aetiology. Neonates are a special case: even in health they 
have high haematocrits (55-65%) compared with adults but this is due more to 
having relatively high MCVs (109-128fL) than to any increase in red cell 
number.174 For these reasons, it is important to the know whether a patient’s
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glucose meter result is likely to be affected either by their haematocrit or their 
red blood cell count per se.
This study has shown that three of the most commonly used meters in the 
United Kingdom exhibit changes in accuracy with sample haematocrit. In 
results consistent with a previous study,138 the Reflolux IIM was found to be 
least affected, the ExacTech intermediate, and the Glucometer Gx worst.
One of the reasons postulated for high haematocrit samples affecting 
glucose strip accuracy is that the greater number of red cells causes a reduction 
in flow of plasma into the reagent pad, resulting in less glucose being available 
for reaction.129 If red cells do indeed block ‘holes’ in the Glucometer and 
Reflolux strip matrices, then it might be expected that the main influence on 
meter measurement would be the red cell count rather than the haematocrit of a 
sample. But if meter accuracy is determined solely by red cell count then it 
should be independent of red cell size. The fact that it was not, and that 
haematocrit was, would suggest that the latter is the true source of test strip 
error.
Unlike the Glucometer and Reflolux, the ExacTech meter measures blood 
glucose via the electrical current produced by the oxidation of glucose through 
an electron mediator (see Chapter 1.4.3). Even with this system it also seems 
likely that variations in haematocrit, rather than red cell number, are 
responsible for the changes in this meter’s accuracy.
The reasons for the differences in meter performance remain speculative. It 
may be partly explained by the Reflolux IIM meter allowing 2 minutes before 
measurement rather than the 50 seconds taken by the Glucometer Gx. The 
longer duration would allow more time for the passage of plasma to the reagent 
layer regardless of sample haematocrit. Although using a completely different 
measuring technique, variations in haematocrit presumably change the 
resistance of the ExacTech test strip to current flow.
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In conclusion, these findings suggest that it is the simple proportion of a 
test strip covered by red cells, not their number, that is the main haematological 
determinant of glucose meter accuracy.
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Chapter 10
The Effect of Haematocrit on 
Intraoperative Blood Glucose Measurement.
100
10.1 Introduction
Chapter 9 confirmed that in vitro changes in haematocrit are responsible for 
errors in test strip glucose measurement and that this effect is independent of 
the component red blood cell count and mean cell volume. However, at the 
time of that study in vivo confirmation of these experimental findings remained 
limited. Only a cross-sectional survey of renal diabetic patients had shown any 
evidence to support the in vitro studies.139 No data existed on the possible 
effect of haematocrit variations within the same individual. This chapter 
presents the results of a study designed to investigate this.
Patients undergoing the procedure of cardiopulmonary bypass routinely 
show a marked reduction in their haematocrit, which potentially provides a 
good model for observing changes in glucose meter measurement. This study 
ascertained whether these intraoperative haematocrit changes could lead to 
spurious test strip glucose measurements in vivo when using three of the most 
commonly used contemporary blood glucose meters.
10.2 Methods
10.2.1 Patients
Ten patients (7 male, 3 female median age 63 years (range 33-79)) who were 
undergoing cardiopulmonary bypass at the Western Infirmary, Glasgow, were 
recruited into the study. None were known to have pre-existing diabetes. Six 
patients had coronary artery vein grafts, three aortic valve and one a mitral 
valve replacement.
10.2.2 Study Design
All patients were premedicated with either temazepam or lorazepam. In 
addition, seven patients were given omnopon and scopolamine 
intramuscularly. Anaesthesia was induced with a combination of midazolam,
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etomidate and fentanyl. In two cases, only the latter anaesthetic agent was used. 
Muscle relaxation was achieved using an appropriate dose of pancuronium. 
Maintenance of anaesthesia involved a combination of fentanyl, nitrous oxide 
and enflurane in 8 patients and fentanyl/propofol in the remaining two. Six 
patients received intraoperative dopamine (2.5-3.5 pg/kg/min) and a further 2 
required 3mg and 8mg of methoxamine.
Cardiopulmonary bypass was performed using a standard technique. This 
involved a pump prime of two litres of Hartmanns solution to which was added 
8,000 units of heparin, 15 mmol of potassium chloride, lOg of mannitol, 50 
mmol of sodium bicarbonate and 750mg of cefuroxime.
Blood samples were obtained before bypass and every 30 minutes 
following for the next two hours. Specimens were collected into a syringe with 
no anticoagulant via an arterial cannula. Each sample was analysed 
immediately by properly calibrated Glucometer II, One Touch II and Reflolux 
IIM meters. The blood samples were also decanted into fluoride oxalate 
vacutainers for the measurement of whole blood glucose by a reference method 
using a YSI Model 23 AM analyser. All reference samples were analysed 
within six hours of collection. Haematocrit was measured on a Coming 288 
analyser (Ciba Coming Diagnostics, Halsted, Essex, UK).
10.2.3 Statistical Analysis
Meter accuracy at varying haematocrits was expressed as a percentage of the 
reference instrument values. Linear regression was by the least squares method. 
Method comparisons between all meter measurements and the reference 
instrument was by the Bland Altman residual plot method.175 Bland Altman is 
a means of comparing a new method with that of an established or reference 
one. The differences between methods (the residuals) are plotted against the 
mean of the two results (for example, see Figure 13.1). Ninety five percent of 
samples are included by the mean residual value ± 1.96SD. If 95% of results
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with the new method are deemed to be acceptably close to the existing method, 
then the new method can be adopted.
10.3 Results
10.3.1 Intraoperative Changes in Haematocrit
Table 10.1 shows the variation in haematocrit and reference blood glucose 
which occurred in the 10 patients during the cardiopulmonary bypass 
procedure.
10.3.2 Meter Accuracy and Changes in Haematocrit
Figures 10.1, 10.2 and 10.3 demonstrate the change in meter accuracy (as a 
percentage of the reference YSI glucose) with variations in haematocrit for the 
Glucometer II, One Touch II and Reflolux II meters respectively. Each figure is 
depicted in the same scale.
For every 10% fall in haematocrit, Glucometer II measurements rose by 
22% and One Touch II measurements fell by 4%. The accuracy of the Reflolux 
II showed no significant relationship to changes in sample haematocrit.
10.3.3 Overall Meter Accuracy
The mean glucose during the study was 5.80 mmol/L. Using Bland Altman 
residual comparisons between the meters and the reference instrument, the One 
Touch II meter showed an overall mean bias of 0.3 mmol/L, with 95% of 
samples falling within +0.86 mmol/L and -0.26 mmol/L of the YSI analyser. 
The mean bias of the Reflolux II was 1.58 mmol/L (95% within +3.40 mmol/L 
and -0.24 mmol/L) and for the Glucometer II this was 3.25 mmol/L (95% 
within +6.18 mmol/L and +0.32 mmol/L).
The One Touch II also showed the best overall correlation with the 
reference analyser (r=0.971, y=0.889x +0.94). Although the Glucometer II
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correlated better than the Reflolux II (r=0.897, y=1.88x -1.86 vs. r=0.787, y=
1 .Olx +1.52 respectively), the effect of haematocrit on the Glucometer II is 
evident by the gradient and intercept of the regression line.
10.4 Discussion
Most published studies have varied haematocrits by either the addition or 
removal of homologous plasma from centrifuged whole blood samples. In 
contrast, Clark et al found that a group of patients with a low mean haematocrit 
due to renal failure gave different glucose test strip results compared to a group 
of controls.139 In the present study we have varied haematocrit in the same 
individuals by a method which routinely occurs during cardiopulmonary 
bypass.
We have shown that Glucometer II glucose measurements vary inversely 
with a reduction in haematocrit. For every 10% fall in haematocrit, there was a 
22% increase in measured glucose. This compares with our in vitro study ( see 
Chapter 9) which showed a 19% increase for the same change in packed cell 
volume.
The same experimental investigation showed that a 10% haematocrit fall 
gave a 6% rise in glucose when measured by the Reflolux II. This change, 
however, was not apparent in our results, presumably because of the relatively 
poor relationship obtained between the Reflolux II measurements and the 
reference YSI instrument.
The One Touch II meter is peculiar to others in that both low and high 
haematocrit samples can give spuriously low glucose readings (see Chapter 
13). Over the haematocrit range of this study, there was a modest 4% fall in 
glucose measurements with every 10% reduction in haematocrit which is 
consistent with the experimental effect of haematocrit found in Chapter 13, 
Figure 13.2. Overall, the One Touch II blood glucose meter performed closest 
to the reference YSI analyser during the period of the investigation.
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It has been recommended that glucose meters should aim to have 
measurements which fall within 15% of the reference method.130 Outwith this 
range errors are more likely to be clinically significant. We have demonstrated 
that the measurement of glucose using test strips can lead to this degree of 
inaccuracy during the procedure of cardiopulmonary bypass. For the 
Glucometer II, a change in haematocrit of less than 10% will confer such a 
difference.
Coronary heart disease is more prevalent in Type 2 (non-insulin-dependent) 
diabetic patients.176,177 This means these individuals may comprise up to 20% 
of coronary artery bypass referrals.178 It is thus especially relevant that 
cardiopulmonary bypass, in particular, should cause this problem in blood 
glucose measurement.
Glucose meter manufacturers have patient haematocrit limits outwith 
which measurements are not recommended (Glucometer II 35-50%, Reflolux II 
35-70%, One Touch I I25-60%). However, these are not always widely 
appreciated, nor is it invariably possible to know the haematocrit of an 
individual at the time of sampling. An awareness of the effect is vital if the 
incorrect administration of intraoperative insulin is to be avoided.
In conclusion, we have demonstrated in vivo variations of test strip glucose 
measurements with the changes in haematocrit experienced during 
cardiopulmonary bypass. This data can presumably be extrapolated to any 
patient who has a low haematocrit and should be borne in mind by clinicians 
when dealing with intraoperative glucose measurement or in situations such as 
in Intensive Therapy Units.
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Chapter 11
The Effect of Variations in Sample pH and p(>2 
on Blood Glucose Meter Measurement.
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11.1 Introduction
Most glucose test strips currently in use employ the enzyme glucose oxidase as 
the basis of their method of measurement (see Chapter 1.4.3). Glucose, 
molecular oxygen and water are the substrates of this enzyme. It therefore 
seems reasonable to suggest that changes in sample oxygen tension may result 
in discrepancies in glucose measurement. In addition glucose oxidase, like all 
enzymes, shows variations in activity with changes in pH. However, before the 
study described in this chapter, the sole effects of sample pH and p 0 2 on 
glucose test strip measurement could not be accurately assessed because of the 
inability to isolate them from the multitude of other blood gas changes which 
are usually present in such samples.
This study describes a novel technique for producing blood samples with 
specified levels of pH, p 0 2 and pC02 and applies it to establish if, and to what 
extent, five of the most commonly used glucose meters in the UK are 
influenced by independent changes in sample pH and p 0 2.
11.2 Methods
11.2.1 Preparation of Blood Samples with Variable pH
On two occasions 21mL of venous blood (haematocrit 42%) was collected in 
lithium heparin sample tubes. One was spiked with a 10% glucose solution (10 
pL in lmL blood) to provide samples with an initial blood glucose 
concentration of 8.75 mmol/L and the other was left unaltered and had a 
concentration of 5.35 mmol/L. In total, five 2 mL samples had increasing 
concentrations of strong acid added (0 to 80pL of 1M HC1) whilst another five 
samples had increasing concentrations of additional strong alkali (0-80pL of 
2M NaOH). Samples with less than 80pL added were made up to this volume 
with 0.9% NaCl. Each sample was stored in a 37°C water bath before being 
tonometered in turn for 20 minutes using an EQUILibrator Model 300
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tonometer (RNA Medical Acton Ma, USA) at 37°C and a constant gas mixture 
of 9.8% 0 2 and 5.6% C 02. This instrument equilibrates the partial pressures of 
a blood sample with that of a connected gas cylinder. On completion, blood 
gases were immediately measured using a calibrated Instrumentation 
Laboratory Model 1302 blood gas analyser (Instrumentation Laboratory (UK) 
Ltd, Warrington, Cheshire, UK). This technique allowed the preparation of 10 
blood samples with a very similar mean p 0 2 (9.09 ± 0.096 (SEM) kPa) and 
pC 02 (5.52 ± 0.024 kPa), but a pH range of 6.54 to 7.73. Throughout the 
procedure, a 2mL blood sample that had 80pL of 0.9%NaCl added (but had not 
been tonometered) was kept in a 37°C water bath.
11.2.2 Preparation of Blood Samples with Variable Oxygen 
Tension
Venous blood was collected and spiked as before to achieve an initial glucose 
concentration of 11.2 mmol/L. The sample was stored in a water bath set at 
37°C. Two millilitres of sample was placed in an Instrumentation Laboratory 
Model 237 tonometer at a temperature of 37°C. The instrument was adapted to 
allow the gas input to come from a Boyles International anaesthetic machine 
(Omeda Ltd., Harrow, Essex, UK) which permitted a variable flow of nitrogen, 
oxygen and carbon dioxide. Blood was tonometered for 5 minutes and then 
immediately measured by a calibrated ABL Model 505 blood gas analyser 
(Radiometer Ltd., Crawley, West Sussex, UK). The flow of gases was set so as 
to achieve a minimal change to mean pH (7.28 ± 0.012) and pC 02 (7.98 ± 
0.25kPa) in 10 separate tonometered blood samples whilst allowing glucose 
measurements on samples with a p 0 2 range of 2.0kPa to 33.6kPa.
11.2.3 Measurement of Blood Glucose
Immediately after blood gas analysis, duplicate blood glucose measurements 
were performed on the following five properly calibrated blood glucose meters:
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the Accutrend, the ExacTech Companion, the Glucometer IIM, the One Touch 
II, and the Reflolux II. Within-assay coefficient of variations (n=10) using the 
Sugar Chex ‘mid’ solution (Streck Laboratories Inc, Omaha, NE, USA) were 
2.9%, 5.2%, 4.9%, 6.6% and 1.9% respectively.
Duplicate reference whole blood glucose measurements were performed on 
an Analox Model GM9 glucose analyser concurrently with the measurements 
performed by the blood glucose meters. This instrument was chosen because it 
deoxygenates the blood sample before analysis and so is unlikely to be affected 
by variations in p 0 2 (see Chapter 3.5.4). However, to prevent the possibility of 
the Analox analyser giving spurious measurements due to changes in pH the 
venous sample stored in a water bath was used as the reference measurement.
11.2.4 Statistical Analysis
Linear regression analysis was performed by the least squares method. 
Reference and meter blood glucose measurements were expressed as a mean of 
two values. Meter accuracy was expressed as a percentage of the reference 
measurement.
11.3 Results
11.3.1 Effect of Sample pH
Table 11.1 describes the relationship of all meters to changes in pH and p 0 2. 
Only the ExacTech showed any significant (p<0.05) linear relationship to 
changes in pH (Figure 11.1). The Accutrend (r=0.022, p=0.952), Glucometer II 
(r=-0.41, p=0.24), One Touch II (r=0.021, p=0.95) and Reflolux II (r=-0.53, 
p=0.12) were unaffected. By extrapolation, compared to a sample of pH 7.40, 
the ExacTech meter underestimated a glucose measurement by greater than 
15% below pH 6.95, and overestimated beyond 15% above pH 7.85.
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11.3.2 Effect of Sample pCT
The meters which showed significant changes in glucose measurement with 
increasing oxygen tension were the ExacTech (r=-0.79, p=0.006) (Figure 
11.2a), Accutrend (r=-0.82, p=0.003) and One Touch II (r=-0.67, p=0.035).
The Glucometer II (r=0.37, p=0.29) and Reflolux II (r=0.33, p=0.36) had no 
association. The relationship of the ExacTech, unlike the other meters, was 
much improved when the oxygen tension was expressed logarithmically (r=- 
0.95, p=0.00002) (Figure 11.2b). Extrapolating from the log plot, the glucose 
measurement by the ExacTech was equal to that of the Analox at a p 0 2 of 
11.5kPa. The meter underestimated by greater than 15% at a p 0 2 below 5.8kPa 
and overestimated to the same degree beyond 22.9kPa. A 15% deviation for the 
Accutrend and One Touch II represented a p 0 2 change of 45kPa and 42kPa 
respectively.
11.3.3 Overall Accuracy of Meters at Varying pH and pO?
During the study, all meters showed a mean bias within 1 mmol/L of the 
reference instrument, but as a result of the effect of pH and p 0 2 on the 
ExacTech meter, it showed the greatest deviation from the Analox in both 
experiments (Table 11.1).
11.4 Discussion
As management decisions are taken according to the results obtained by ward 
based blood glucose meters,179 it is particularly important that both clinicians 
and patients are aware of all the potential sources of error in the meter system 
they use.
Using the recommendations that glucose meters should aim to have 
measurements which fall within 15% of the reference method,130 we have 
shown that the ExacTech meter can fall outwith these limits below a blood pH 
of 6.95 before any other possible sources of error are taken into account. Thus,
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a severely acidotic patient may obtain an inappropriately low result on using 
this meter. If the acidosis is due to diabetic ketoacidosis the patient is also 
likely to have a raised haematocrit due to dehydration. We have already shown 
that in the ExacTech meter a 10% increase in haematocrit leads to a 15% fall in 
measured glucose (see Chapter 9). This may therefore compound any 
underestimate in glucose measurement.
The ExacTech meter also showed the greatest variability in measurements 
taken at different blood oxygen tensions. At the sample pH we obtained, the 
meter was accurate at a p 0 2 of 11.5 kPa but gave an error of greater than 15% 
at oxygen tensions below 5.8kPa and above 22.9kPa. The former oxygen 
tension may occur in hypoxic patients or if a venous sample is used instead of 
capillary. Indeed, Matthews et al found the ExacTech meter to have a 10% 
positive bias when using venous instead of capillary blood in 182 patients.180
Our oxygen tension findings are also consistent with those of Halloran181 
except his meter measurements, even at a normal capillary p 0 2, showed an 
additional positive bias of around 30%. The bias is most probably ascribable to 
the fact that the equilibrating gas he used was a nitrogen/oxygen mixture which 
lacked carbon dioxide. All the samples were therefore likely to have been 
rendered severely alkalotic and thus subject to the pH changes described above.
Both the Accutrend and the One Touch II meters demonstrated reductions 
in meter measurements with increasing p 0 2. However, a 15% error due to this 
effect alone would not occur in clinical practice.
The reasons remain speculative as to why the ExacTech electrochemical 
method for glucose measurement should show the largest error in both 
experiments. Experimental results from a prototype electrochemical method 
with non-physiological samples suggested the ExacTech meter would be 
unaffected by changes in pH.182 However, it would appear the ExacTech 
implementation of this method, when using blood as samples, can be 
influenced, presumably by redox reaction interference from hydrogen ions. The
I l l
decreasing ExacTech meter measurements found when increasing sample 
oxygen tension may result from the use of the electron mediator ferrocene for 
glucose measurement: increasing competition between oxygen and ferrocene 
for the glucose oxidase enzyme is likely to result in the production of 
increasing amounts of hydrogen peroxide relative to the formation of the 
reduced form of ferrocene, ferricinium (see Figure 1.2). Hydrogen peroxide is 
less easily reoxidised than ferricinium which means test strip current flow is 
likely to be diminished and so any glucose concentration measured is apt to be 
reduced.
Our findings are of especial clinical relevance in the management of 
acutely unwell patients. As well as those individuals already mentioned with 
severe diabetic ketoacidosis, patients in Intensive Therapy Units commonly 
have acid-base disturbances and/or require ventilation for respiratory failure. 
Use of the ExacTech meter in these situations is more liable to lead to 
erroneous results.
In conclusion, changes in pH and p 0 2 affect the most commonly used 
blood glucose meter systems variably. Whilst there is little question that the 
ExacTech Companion meter can perform accurately in well patients using 
capillary blood,63 caution may need to be exercised when interpreting 
measurements in severely acidotic or hypoxic patients.
Since the publication of this study the other electrochemical meter 
marketed by Medisense, the Companion 2, has become widely available and 
the test strips have recently become obtainable on NHS prescription. Initial 
experience with this meter would suggest that although it is still affected by 
variations in sample haematocrit, the addition of a third electrode in the strip 
has minimised the effect that sample p 0 2 has on meter accuracy.183 This would 
help explain the finding that results from venous samples are now 
insignificantly different from capillary ones when using this test strip.184 It 
would therefore seem appropriate from the evidence in this chapter that the
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company continue to concentrate their efforts on the marketing of this product 
rather than the ExacTech.
Chapter 12
The Effect of Sample Haemolysis on 
Blood Glucose Meter Measurement.
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12.1 Introduction
Extra-laboratory measurement of analytes such as blood glucose has led to an 
increase in the use of whole blood rather than serum or plasma as a specimen 
for biochemical measurement. Whilst the use of whole blood in a clinical 
setting has the advantage of being convenient, it is not possible, unlike plasma 
or serum, to tell if the sample being used is in any way haemolysed.
When a new method is introduced into a laboratory it is routine practice to 
assess the extent to which it is affected by sample haemolysis. However, before 
this study, the effect of haemolysis on glucose meter results had not been 
established, presumably because the samples usually used (serum and plasma 
spiked with haemoglobin) would be inappropriate for assessing glucose test 
strips which can be affected by sample haematocrit (see Chapters 9 and 10) as 
well as sample pH and p 0 2 (see Chapter 11). A rapid means of obtaining 
samples which contained lysed red cells together with their red cell membranes 
was required. This study has adapted a method used for obtaining enzymes 
from white cells (sonication) to establish if, and to what extent, seven of the 
most commonly used glucose meters in the UK are influenced by varying 
degrees of sample haemolysis.
12.2 Methods
12.2.1 Preparation of Samples with Variable Haemolysis
Forty millilitres of venous blood (glucose concentration 7.35 mmol/L, 
haematocrit 40.0%) was collected without a tourniquet into lithium heparin 
sample tubes. Six millilitres was completely haemolysed by ten 1 second 
exposures to ultrasound using a MSE Soniprep 150 sonicator (MSE Ltd. 
Loughborough, UK). The sonicated blood (p02 4.0kPa), including the lysed 
cell membranes, was then immediately added to untreated blood (p02 5.0kPa) 
in increasing amounts (0 to 850pL) to yield 9 four millilitre samples with
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increasing levels of haemolysis. The calculated plasma free haemoglobin 
concentrations (0, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, and 5 g/dL) were confirmed at 
the end of the study by measurement in a Philips Model PU150 (Philips 
Scientific Ltd. Cambridge, UK) scanning spectrophotometer.185 The free 
haemoglobin concentrations represented the proportion of intact red cells 
falling from 40% of blood volume to 31.5%.
12.2.2 Measurement of Blood Glucose
Each sample (in random order) was measured in duplicate on the following 
properly calibrated blood glucose meters using the August ’94 generations of 
test strips: the Accutrend (12 second strip), the Companion 2, the ExacTech 
Companion, the Glucometer IIM, the Glucometer 4, the One Touch II and 
Reflolux II. Forty microlitre sample volumes were used throughout.
The reference glucose instrument used in the study was an Analox Model GM9 
glucose analyser. This is able to measure glucose in plasma, in whole blood 
with intact red cells or in lysed whole blood.186 Duplicate reference 
measurements were performed on each sample concurrently with the meter 
measurements.
12.2.3 Statistical Analysis
Linear regression analysis was performed by the least squares method. 
Reference and meter blood glucose measurements were expressed as a mean of 
two values. Meter accuracy was expressed as a percentage of the reference 
measurement.
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12.3 Results
12.3.1 The Effect of Haemolysis on Blood Glucose Meter 
Measurement
Only the Accutrend showed any significant (p<0.05) linear relationship to the 
degree of haemolysis in the sample (Figure 12.1). Below a plasma 
haemoglobin concentration of 5g/dL, all other meters demonstrated results 
which were within 15% of the value obtained on the untreated sample.
12.3.2 The Effect of Extreme Haemolysis on Blood Glucose Meter 
Measurement
Using the completely haemolysed sonicated blood, extreme levels of 
haemolysis (14.2 g/dL) were found to affect the Accutrend meter (glucose 
value 108% greater than reference), the ExacTech (+98%), the Glucometer II 
(-32%) and the Companion 2 (-41%). The Reflolux gave an error code using 
completely haemolysed blood. The One Touch II and Glucometer 4 meters 
again gave results which were within 15% of the untreated sample.
12.4 Discussion
Manufacturers of glucose meters often recommend that their products be used 
exclusively with capillary blood samples. A degree of haemolysis in these 
samples is almost unavoidable.187 Moreover, it has been estimated that, even 
when using careful techniques, around 5% of capillary specimens are likely to 
show visible red cell lysis.188 Thus any effect that haemolysis may have on 
glucose meter measurements cannot be underestimated, especially since it is so 
difficult to detect.
In this study we have shown that, below 5g/dL haemolysis, the Accutrend 
meter shows an increasingly positive bias with increasing degrees of 
haemolysis. Using the recommendation that glucose meters should aim to have 
measurements which fall within 15% of the reference method,130 and that
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outwith this range errors are more likely to be clinically significant, this study 
has shown that for every 7% of red cells lysed, such a 15% increase in the 
glucose value of the Accutrend meter is obtained.
Together with the Accutrend meter, the ExacTech, the Glucometer II and 
Companion 2 meters all showed large (>30%) fluctuations in glucose 
concentration when using an extremely haemolysed sample. While a similar 
sample would hopefully not be found often in clinical practice, it is interesting 
to speculate that this may be one of the causes of ‘flier’ results obtained by 
meter users.
The reason why the Accutrend meter should be most affected by 
haemolysis is unlikely to be due to any difference in the proportion of intact 
red cells to plasma since this meter is relatively unaffected by variations in 
haematocrit.189 The Accutrend is also unaffected by changes in sample p 0 2 (see 
Chapter 11) so the use of venous blood, rather than capillary, should not have 
affected our results. Presumably, free haemoglobin presents a darker colour at 
the colour field of the Accutrend test strip. This leads to a lower percentage 
reflectance and hence a higher blood glucose measurement. Since intact red 
cells are usually retarded by the glass fibre matrix of the test strip189 then, 
unlike haemolysed specimens, haemoglobin in non-haemolysed samples would 
not normally have the opportunity to interfere.
It is of relevance that often the capillary samples most difficult to obtain 
(and therefore most likely to show haemolysis) are those found in situations 
where the patient has compromised peripheral circulation due to being acutely 
unwell. Therefore, use of the Accutrend meter in such situations may more 
commonly lead to spuriously raised blood glucose results.
In conclusion, haemolysis in a blood sample would appear to affect blood 
glucose meter measurement by varying degrees depending on the instrument 
used. Whilst a number of meters showed inaccuracies using extremely 
haemolysed samples, the Accutrend meter demonstrated a positive bias at more
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modest degrees of red cell lysis. Thus, an unexpected result may need to be 
treated with caution, confirmed visually, and repeated by either the meter or, if 
relevant, in a laboratory.
Personal communications with Boehringer Mannheim since the publication 
of this study have confirmed that the company were aware of a problem with 
sample haemolysis when using their Reflotron analyser. Since the Accutrend 
meter is based on the same technology, they were not surprised we saw a 
similar effect, although they felt the problem was unlikely to be significant in 
most clinical situations.
Chapter 13
A Laboratory Evaluation of the 
One Touch II Blood Glucose Meter.
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13.1 Introduction
In 1992 a new blood glucose meter, the One Touch II from Lifescan Ltd, was 
introduced into the UK after being successfully launched in the United States.
It was unique in addressing the 4 principal clinical problems associated with 
extra-laboratory blood glucose analysis at that time, namely, errors due to the 
size and placement of the blood sample, the timing of the test and wiping of 
blood from the test strip.130 It achieved this by flagging insufficient samples, 
automatically timing the test on correct sample placement, and requiring no 
wiping of the sample from the test strip. In the UK, the ExacTech meter from 
Medisense Ltd was the only other contemporary meter which offered close to 
this degree of sophistication. However, although the ExacTech also employed a 
‘non-wipe’ technique, even this meter was unable to detect small samples 
consistently, start timing automatically, have an analytical range of 0- 
33.3mmol/L, keep a date and time stamped record of the last 255 meter 
readings, record quality control results separately, or download this information 
into a PC.
Before the potential advantages of this meter could be confirmed clinically, 
it was important to assess the adequacy of the meter when tested in a laboratory 
environment to see if the problems known to affect other meter strips were 
applicable to this instrument. This study describes such an evaluation.
13.2 Methods
13.2.1 Study Design
Accuracy of the meter was assessed in comparison with a YSI Model 23 AM 
blood glucose analyser. Forty eight samples were collected in K2EDTA 
anticoagulant. While the glucose values of some samples were allowed to fall 
by glycolysis, others were spiked with a 10% glucose solution to achieve
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hyperglycaemic samples. The mean value of duplicate measurements was used 
in both instruments.
Imprecision of the meter was obtained using both EDTA whole blood and 
manufacturer’s control solution samples. Samples designated as having low, 
mid and high glucose concentrations were analysed 20 times to provide a 
measurement of within-assay precision. Between-assay precision was assessed 
using the same control solutions over a 20 day period.
To assess the effect of haematocrit on meter measurements, EDTA samples 
from 2 non-diabetic individuals were spiked with 10% glucose to obtain YSI 
blood glucose concentrations of 10.0 and 10.3 mmol/L at 40% haematocrit. 
They were then adjusted to obtain haematocrit values ranging from 0-60% by 
the addition or removal of homologous plasma. Two glucose samples from 
each subject were used in both instruments.
Common interferents of the glucose oxidase enzyme system were added 
individually to whole blood samples to assess their effect on One Touch II strip 
measurement. Pathological concentrations of bilirubin (up to 317pmol/L), 
lipaemia (up to lOOOmg/dL Intralipid), urate (up to 1.2mmol/L) and ascorbate 
(up to 50mg/L) were investigated. In addition, specimens with toxic and non­
toxic concentrations of paracetamol (up to 300mg/L), salicylate (up to 
350mg/L) and ethanol (up to 400mg/dL) were used. All results were adjusted 
for any specimen dilution incurred by spiking.
The effect of sample volume on the imprecision of the One Touch II 
instrument was assessed using sample volumes 5-40pL using an adjustable 
lOOpL Gilson air displacement pipette. Measurements below 5pL used an 
Absoluter positive displacement pipette.
13.2.2 Statistical Analysis
Comparison of meter accuracy with the YSI instrument was by a Bland Altman 
residual plot.175 Imprecision measurements were expressed as coefficients of
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variation (CV’s). In the haematocrit experiment, One Touch II glucose values 
were expressed as a percentage of the YSI result and the curve fit used a fifth 
order polynomial interpolation.
13.3 Results
13.3.1 Accuracy
Specimen values from 0.1 to 29.2 mmol/L were obtained. Figure 13.1 shows 
the residual plot comparison with the YSI instrument. The One Touch II 
showed a mean bias of +0.55 mmol/L (95% Cl +0.22 to +0.89) with 95% of 
samples (±1.96 SD) between +2.83mmol/L (95% Cl +2.25 to +3.42) and 
-1.72mmol/L (95% Cl -2.31 to -1.14).
13.3.2 Imprecision
Table 13.1 shows the within-assay and between-assay imprecision for both 
control and whole blood solutions.
13.3.3 Haematocrit
Figure 13.2 shows a graphical representation of One Touch II meter accuracy at 
different haematocrit values. Results only deviated by greater than 15% from 
the YSI values at haematocrits above 50%.
13.3.4 Interference
Tables 13.2a and 13.2b describe the effect of the chosen interferents on glucose 
measurement taking into account specimen dilution. A change of greater than 
15% was not observed in any specimen used.
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n Mean S.D. C.V.
Within-Assay
Control low 2 0 3.07 0.065 2.14
mid 2 0 6 . 2 0 0.141 2.28
high 2 0 19.49 0.477 2.45
Blood 1 2 0 3.65 0.069 1 . 8 8
2 2 0 7.32 0.146 2 . 0 0
3
Between-Assay
2 0 15.71 0.429 2.73
Control low 1 2 3.08 0.062 2 . 0 2
mid 16 6.13 0.189 3.08
high 1 2 18.9 0.565 2.98
Table 13.1 Table showing within-assay and between-assay 
imprecision (coefficient of variation) of the 
One Touch II blood glucose meter.
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SALICYLATE 0 mg/L 175 mg/L 350 mg/L
Sample A 8.3 8.35 8.2
Sample B 7.85 7.875 8.08
URATE 0.3 mmol/L 0.8 mmol/L 1.2
mmol/L
Sample A 7.8 7.7 7.5
Sample B 7.95 7.77 8.30
ETHANOL
Sample A 
Sample B
ASCORBATE
Sample A 
Sample B
PARACETAMOL
Sample A 
Sample B
0 mg/dL
8.25
7.8
lOmg/L
8.3
7.8
Omg/L
8.55
7.95
80 mg/dL
8.35
8.0
3 Omg/L
8.3
7.7
30mg/L
8.54
7.93
400 mg/dL
8.25
8.0
50mg/L
8.08
7.42
300mg/L
9.18
8.14
Table 13.2a Effect of increasing concentrations of 
potential interferents on the One Touch II 
glucose meter in 2 blood samples (A and B).
BILIRUBIN
Sample Bilirubin YSI One Touch II
(umol/L) (mmol/L) (mmol/L)
A 51 16.0 17.3
B 135 14.2 15.4
C 156 14.3 15.5
D 237 13.5 13.8
E 317 13.8 14.5
LIPAEMIA
mg Intralipid/dL YSI One Touch II
0 9.8 9.7
1 0 0 9.6 9.6
2 0 0 9.5 9.5
300 9.4 9.6
400 9.4 9.6
500 9.3 9.5
600 9.2 9.4
700 9.2 9.2
800 9.1 9.2
900 8.9 8.7
1 0 0 0 8 . 8 9.4
Table 13.2b Effect of increasing concentrations of
potential interferents on the One Touch II
glucose meter.
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13.3.5 Sample Volume
Measurements were flagged as insufficient with sample volumes of less than 
3pL. Table 13.3 shows the effect on imprecision when using both air 
displacement and positive displacement pipettes. At sample volumes of less 
than 5pL, the meter commonly interpreted the sample as being that of a control 
solution.
13.4 Discussion
This study showed that for most samples likely to be encountered in clinical 
practice the One Touch II is a robust instrument for measuring blood glucose, 
at least in a laboratory setting.
When assessing the accuracy of the meter, all samples bar one (which had a 
glucose value of 0.4mmol/L) were within 15% of the reference YSI instrument. 
Therefore, in the laboratory, this meter did not report any results which could 
be described as clinically unacceptable.
Imprecision was similarly impressive. When using either control solutions 
or whole blood specimens, the within-batch coefficients of variation were all 
less than 3%. Surprisingly, the between-assay results were little different to 
those obtained within-assay.
The One Touch II showed a peculiar response to changes in blood sample 
haematocrit. Most meters show a linear response to increases in haematocrit, so 
that low haematocrit specimens give falsely high results and vice versa (see 
Chapter 9). However, while high haematocrit samples indeed gave spuriously 
low results, the One Touch II showed only minor fluctuations in glucose results 
at low haematocrits. In fact, results obtained with 0% haematocrit (i.e. plasma) 
samples were as accurate as those obtained when using specimens with normal 
packed cell volumes. Nevertheless, the effect shown at high haematocrits 
means that in patients with high packed cell volumes (e.g. in neonates,
Volume n Mean SD CV
(l^L) (mmol/L) (mmol/L) (%)
Using Adjustable IOOjliL Air Displacement Pipette:
5 10 4.34 0.495 11.4
10 10 4.77 0.313 6.56
15 10 4.50 0.416 9.25
20 10 4.46 0.315 3.03
25 10 4.40 0.240 5.46
30 10 4.38 0.148 3.37
40 10 4.68 0.103 2.21
Using Positive Displacement Pipette:
3 10 4.17 0.266 6.38
5 10 4.83 0.164 3.40
Table 13.3 Effect of sample volume on the within-assay
imprecision of the One Touch II glucose
meter.
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dehydration or chronic obstructive airways disease) the results require to be 
interpreted with caution.
As explained in Chapter 2.4.3, interference from endogenous and 
exogenous reducing agents can affect the glucose oxidase enzyme system. In 
addition, colorimetric interference and the quenching of colour development 
can arise from icteric and lipaemic samples. This study showed that, even with 
extreme degrees of chemical pathology or drug toxicity, the One Touch II is 
unlikely to give unacceptable results.
The manufacturers of contemporary glucose meter ‘wipe’ systems usually 
recommended that sample volumes should be in excess of 15pL. In many cases 
this is not achieved, not only because of a poor skin puncture but also because 
users are given no guide from the meter as to whether samples are sufficient or 
not. This investigation showed that even sample volumes of only 3pL could 
give accurate and precise results with this meter, although on occasions this 
was recorded as a control sample in the meter memory. At volumes below 3pL 
it was not possible to cover the entire reagent pad of the strip with blood so, 
appropriately, the meter would flag that the placed sample was insufficient.
The effect of sample pH, p 0 2 and haemolysis on the One Touch II are 
described in Chapters 11 and 12 and show that the meter is largely unaffected 
by any variations in these parameters.
In conclusion, with the caveat of high haematocrit samples, the One 
Touch II meter would appear to show a good laboratory performance, 
especially when dealing with potential interferents and low volume samples.
Chapter 14
A Ward Comparison Between the 
One Touch II and Glucometer II 
Blood Glucose Meters.
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14.1 Introduction
We have shown that the One Touch II blood glucose meter could give accurate 
and precise measurements when used by laboratory personnel (see Chapter 13). 
However, while a number of other systems using reflectance photometers also 
worked well in both the laboratory setting190’191 and in controlled studies192, it 
was found they could give spuriously good results when compared to nursing 
staff using the meter under less than ideal conditions.193’194
To establish if the promising laboratory performance of the One Touch II 
conferred an improvement in ward glucose measurement, we performed a six 
week evaluation of the meter in a medical ward with a specialist interest in 
patients with diabetes, and compared it to the existing Glucometer II system in 
use.
14.2 Methods
14.2.1 Patients
Twenty seven acute admissions to Ward 7A, Gartnavel General Hospital, 
Glasgow participated in the study. This is a ward with a specialist interest in 
diabetes.
14.2.2 Study Design
All the nursing staff (comprising student nurses to ward sister) from Ward 7A 
were involved in the study. They had all been previously given official 
instruction on how to use the existing Glucometer II system. The One Touch II 
meter was demonstrated to them by one of the Diabetes Nurse Specialists in 
the ward.
Two extensively used One Touch II meters were used to complement the 2 
Glucometer II meters already present on the ward. Each meter in use was 
checked daily using control solutions supplied by the manufacturers. The
127
Glucometer II meters also participated in a manufacturer’s quality assurance 
scheme within the hospital and were given an accuracy rating of ‘good’, which 
is the highest grade achievable.
For a six week period, the 27 acute admission patients had 267 capillary 
blood glucose measurements taken by the nursing staff from a single capillary 
stab. The Glucometer II instrument was used first followed by the One 
Touch II. This order of sample application was used for three reasons. Firstly, 
since the Glucometer II requires a larger sample volume, it was likely that this 
meter would obtain the greatest amount of blood if always used first. Secondly, 
it meant that the nursing staff performing the Glucometer test would conduct it 
as close to the routine manner as possible. Lastly, the Glucometer II (unlike the 
One Touch II) does not indicate clearly if the blood volume is insufficient, so if 
used second with a small sample may have lead to erroneous results.
Blood has to be applied to the One Touch II test strip whilst in the meter.
To prevent cross infection between patients the manufacturer’s disposable 
transfer pipettes were used.
In 129 of the measurements the investigators obtained at least 25pL of 
heparinised capillary blood from either the same finger jab or from a second 
performed directly afterwards. These samples were measured on a YSI Model 
23 AM blood glucose analyser which was sited on the ward. This analyser was 
cilibrated twice daily and all samples were measured within 15 minutes from 
collection.
Recent (within 1 -3 days) haematocrit measurements were obtained on 
pitients comprising 250 of the samples.
At the end of the study, the participating nursing staff were given a simple 
qiestionnaire to complete comparing different aspects of the two meters. They 
vere asked to tick if they felt the One Touch II was the same, better, much 
bitter, worse or much worse than the Glucometer II in terms of (i) ease of use;
128
(ii) feel/robustness and (iii) confidence in results. Finally they were asked 
which meter they preferred overall.
14.2.3 Statistical Analysis
Method comparison between the two meters used Bland Altman residual 
plots.175 Linear regression used the least squares method.
14.3 Results
14.3.1 Glucose Meter Accuracy Compared with Reference 
Instrument
Using Bland Altman ‘limits of agreement’ between the meters and reference 
the One Touch II showed a mean bias of +0.44 mmol/L (95% Cl 0.20 to 0.67) 
with 95% of samples (±1.96SD) falling within +3.08 mmol/L (95% Cl 2.68 to 
3.49) and -2.26 mmol/L (95% Cl -2.62 to -1.80) of the YSI analyser (Figure 
14.1). The Glucometer II had a mean bias for all samples of +0.96 mmol/L 
(95% Cl 0.54 to 1.38) with 95% of samples falling between +5.62 mmol/L ( 
95% Cl 4.89 to 6.34) and -3.71 mmol/L (95% Cl -4.43 to -2.98) (Figure 14.2).
Results were within 15% of the reference in 107 out of 129 (82.9%) 
measurements using the One Touch II and 82 of the 124 (66.1%) 
measurements performed on the Glucometer II. Of the samples below 4 
mmol/L with concurrent YSI measurements, 4 out of 11 Glucometer II results 
were within 15% and 7 out of 11 within 30% of the reference. The One Touch 
II had 6 from 11 within 15% and 11 from 11 within 30%.
The One Touch II was found to be as or more accurate than the Glucometer 
II in 106 out of 129 (82.2 %) samples.
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14.3.2 Glucose Meters Accuracy Over Same Analytical Range
Correlation of the One Touch II meter against the YSI for the samples over the 
entire meter range was as follows: r=0.969, pO.OOOOl, y= 0.982x +0.617. The 
correlation over the same analytical range as the Glucometer II (2.0-22.0 mmol 
/L) showed: r=0.953, pO.OOOOl, y= 1.047x +0.08. The same correlation for 
the Glucometer II meter demonstrated: r=0.865, pO.OOOOl, y= 0.973x +1.20.
14.3.3 Glucose Meter Accuracy Over Recommended Haematocrit 
Ranges
The manufacturers of the One Touch II meter recommend samples should have 
a haematocrit between 25-60%. For the Glucometer II, this is 35-50%. The 
respective correlations of these meters with the YSI were r=0.974 and r=0.876 
within these haematocrit limits.
14.3.4 Agreement Between Meters
The correlations between the two meters were r=0.896 for all samples and 
r=0.893 for those with concurrent YSI measurements.
14.3.5 Measurements Outwith the Analytical Range of the 
Glucometer II
There were 17 occasions during the study period where the One Touch II meter 
was able to give a measurement which exceeded the upper analytical limit of 
the Glucometer II. On 7 of these instances the One Touch II recorded a glucose 
concentration greater than 25 mmol/L of which 3 were above 30 mmol/L. No 
samples were recorded as exceeding the analytical range of the One Touch II 
during the assessment.
No investigation specimens were measured by the Glucometer II as being 
below its lower measurement limit (2 mmol/L).
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14.3.6 Questionnaire Results
Of the five nursing staff who responded to the questionnaire, four felt the One 
Touch II ease of use, feel/robustness and confidence in results were ‘better’ or 
‘much better’ than that of the Glucometer II. The remaining nurse felt the 
former two attributes were the ‘same’ for both meters but had ‘much better’ 
confidence in the One Touch II results. All that replied preferred the One 
Touch II meter overall.
14.4 Discussion
In this study we attempted to give a comparison between two blood glucose 
monitoring systems which was more likely to reflect the measurements 
obtainable in a clinical setting rather than those achievable under laboratory 
conditions.
We found the One Touch II meter to perform closer to the reference YSI 
blood glucose analyser than the Glucometer II in both direct correlation and 
‘limits of agreement’. As a result, the One Touch II meter proved to equal or 
better the Glucometer II in 82% of measurements.
In this study, when using the recommendation that glucose meters should 
aim to have measurements which fall within 15% of the reference method,130 
83% of One Touch II and 66% of Glucometer II results achieved this goal. 
Measurements at or near the hypoglycaemic range were of particular 
importance. At these concentrations the same deviation from the reference will 
yield a proportionately larger percentage error. At measurements of less than 
4 mmol/L both meters had results which were greater than 15% from the YSI, 
but only the Glucometer II had ones which were beyond twice this desirable 
maximum error.
We have shown that variations in haematocrit are the sole haematological 
measurement responsible for discrepant glucose test strip results, with the 
Glucometer II showing particular susceptibility (see Chapter 9). However,
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when only considering samples within both meter manufacturers recommended 
haematocrit limits the One Touch II still compared more favourably with the 
reference than the Glucometer II.
The 17 cases during the evaluation period where the One Touch II gave a 
measurement which was outwith the analytical range of the Glucometer II are 
likely to have prevented unnecessary venepuncture for additional emergency 
blood glucose measurements by the biochemistry laboratory. This only applies, 
of course, where the individual has had a high blood glucose concentration 
previously confirmed by the laboratory and whose condition is not worsening. 
In this situation, as well as being beneficial to the patient (by allowing a 
quicker therapeutic response) this also has cost implications to a diabetic unit.
The fact that nursing staff unanimously preferred using the One Touch II 
meter cannot be overlooked and may indicate the potential for greater 
compliance in self-monitoring of blood glucose.
In conclusion, the potential advantages of the One Touch II meter over the 
Glucometer II in the setting of a diabetic ward would appear to have resulted in 
better meter accuracy, fewer blood glucoses too high to be measured and a 
greater user preference.
Since the publication of this study it has been interesting to note that the 
two dominant glucose meter manufacturers in the UK (Boehringer Mannheim 
and Bayer) have responded to products such as the One Touch II by developing 
instruments which mimic many of the features found in this meter. For 
example, with the Accutrend Alpha from Boehringer Mannheim, blood is also 
applied to a strip already inserted into the meter and timing of the test starts 
automatically on sample application. In common with all new glucose meters, 
this instrument also features a ‘non-wipe’ system. In addition, meters such as 
the Accutrend and Companion 2 now demonstrate the ability to record date and 
time stamped results in the meter memory for future downloading into a PC, if 
necessary.
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It is hoped that the meter improvements from these manufacturers will, like 
the One Touch II, improve their ease of use and their accuracy of results.
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Chapter 15
A Patient Comparison of the 
One Touch II and Accutrend 
Blood Glucose Meters.
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15.1 Introduction
The new generation of blood glucose meters can perform significantly better 
than older systems when used in a ward setting (see Chapter 14). However, the 
introduction of new blood glucose systems to the UK has left diabetic patients 
with a bewildering choice of at least 15 different meters. Often the newer 
meters also appear to have similar features to one another, thereby making a 
choice even more difficult. For example, the One Touch II and Accutrend 
meters both epitomise the recent advances that have occurred in non-wipe 
technology, analytical range, reduction in test time and recording of patient 
results in meter memories. To see if differences exist between the newer 
meters, part of this study has compared the relative accuracy and acceptability 
of the One Touch II and Accutrend blood glucose meters when used by 
diabetic patients.
Not every diabetic out-patient clinic has the resources to fund on-site 
glycated haemoglobin measurement, so in-clinic random glucose measurement 
is often used as an immediate assessment of glycaemic control. As an 
alternative, this study has also assessed the relative usefulness of using the 
mean value of the glucose results stored in the memories of the One Touch II 
and Accutrend meters.
15.2 Methods
15.2.1 Patients
Seventeen diabetic patients (10 male, 7 female, 15 Type I, 1 insulin treated 
Type II, median age 39 years, range 18-69, median duration of diabetes 8 years, 
range 0-27) attending the diabetic out-patient clinic, Gartnavel General 
Hospital, Glasgow participated in the study. Patients had either not used a 
meter previously or were using one and had expressed a preference to change. 
None had prior experience of the meters used in the study.
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15.2.2 Study Design
A 16 week crossover study was performed. The diabetic patients were 
randomly assigned either a One Touch II or Accutrend blood glucose meter for 
eight weeks before crossing over to the other. They were educated in the use of 
both meters by the same Diabetes Nurse Specialist.
Patients were asked to perform 4 pre-prandial blood glucose measurements 
per day on 3 occasions per week. These were recorded using a diary and 
confirmed by the meter memories. In addition, to assess the meter accuracy, the 
patients were invited to attend weekly for a simultaneous measurement of 
capillary whole blood glucose by the meter (using their own technique) and by 
a reference Analox Model GM9 instrument. The sample used for the reference 
measurement was from either the same finger stab as that made by the patient 
or from one taken directly afterwards.
Haemoglobin A \ c was also measured in the patients using a Bayer 
DCA2000 instrument at the start of the study, at meter changeover and at study 
end. Random clinic glucose measurements using the reference instrument were 
also obtained at these times.
At the end of the study, patients were allowed to keep the meter they had 
preferred using.
15.2.3 Statistical Analysis
Linear regression used the least squares method. Bland Altman residual plots 
were used for glucose method comparisons. Comparison of glucose values 
with HbAjc used the McNemar test.
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15.3 Results
15.3.1 Meter Accuracy
The results of both meters correlated with those of the reference instrument 
(One Touch II, r= 0.966, n=132; Accutrend, r=0.885, n=120). The One Touch 
II showed a mean bias of -0.63 mmol/L (95% within +2.71 and -3.97 mmol/L) 
and the Accutrend a mean bias of -0.73 mmol/L (95% within +4.75 and-6.21 
mmol/L)(Figures 15.1 and 15.2). Seventy five percent (99/132) of One Touch 
II and 74% (89/120) of Accutrend meter results were within 15% of the 
reference value (NS difference).
15.3.2 Meter Acceptability
At study completion, 15 out of the 17 patients chose the One Touch II as their 
preferred meter (p<0.005). The reasons for choosing the One Touch II were 
cited as either due to the improved ease of use of the One Touch II or the fact 
that the Accutrend did not operate reliably at temperatures below 15°C. Of the 
2 who chose the Accutrend, one preferred its shorter test time (12 seconds vs. 
45 seconds) while the other, with impaired vision, favoured the larger results 
display.
15.3.3 Meter Memory Values and HbAir
Patients performed a total of 3,524 meter measurements. A mean of 112 One 
Touch II and 107 Accutrend measurements were recorded by each user. 
Haemoglobin A \ c values at study crossover and study end were obtained on 16 
patients. For each of the eight week periods, the mean Accutrend and One 
Touch II glucose values correlated with the subsequent HbAjc measurement 
(p<0.00001, Figure 15.3). This was not the case when using the random clinic 
value (p=0.14, Figure 15.4). This meant that the average meter glucose values 
predicted more HbAjc results within 2 standard deviations of the assay (i.e.
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0.6% HbAjc, see Chapter 5) than the random glucose measurement (23/32 vs. 
11/32, p=0.003).
15.4 Discussion
Improvements in glucose meter technology are only of use if it can be 
demonstrated that patients are happy using these meters and can obtain 
acceptably accurate results. Although the meters used in this study have many 
similar features, they also differ in a number of respects. For example, the 
Accutrend meter can obtain results in 12 seconds compared to 45 seconds with 
the One Touch II while the Accutrend requires a larger sample volume than the 
One Touch II (11 pL vs. 3-5pL). Additionally, the One Touch II, unlike the 
Accutrend, displays written prompts for each process in the meter 
measurement but does not have the Accutrend’s automatic bar-code calibration 
of test strips.
For all these differences, this study has shown that the One Touch II and 
Accutrend blood glucose meters show similar accuracy to one another when 
used by the same diabetic patients. Both meters had 74% of samples achieving 
the recommended goal of results within 15% of the reference instrument 
value.130 This compares to the 83% of One Touch II samples which met this 
standard when the meter was used by trained nursing staff (see Chapter 14). In 
contrast, when using direct correlation and residual plots, the One Touch II 
showed greater overall agreement with the reference instrument than the 
Accutrend. This implies that the Accutrend readings which are not within 15% 
of the reference tend to be less accurate than the One Touch II.
The fact that 15 patients preferred to keep the One Touch II in preference to 
the Accutrend would appear to indicate that patients consider ease of use and 
reliability in meter measurement more important than simply the speed with 
which the test is performed.
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It is of interest that the mean glucose value obtained by patients on their 
meter over the period of 8 weeks was so closely related to their subsequent 
HbAjc value (Accutrend r= 0.79, One Touch II r= 0.81, together r=0.79). In a 
clinical situation, such a value recorded in the meter memory of insulin treated 
patients would appear to be a superior means of assessing glucose control than 
a random glucose measurement performed before an out-patient consultation 
(r=0.27, p=0.14). Predicting a HbAjc value outwith 2 standard deviations of 
the true value may completely misclassify the glycaemic control of a patient 
when using European guidelines (see Chapters 4 to 7). In this study, the 
average meter glucose concentration predicted nearly three quarters of the 
patients to within 2SD, while with the random clinic concentration this was 
only one third. Therefore, for clinicians and patients attending clinics without 
the funding for on-site glycated haemoglobin measurement, the use of the 
average value in meter memories would appear to be a more reliable indicator 
of glucose control.
On a practical note, the Accutrend meter requires downloading of its 
recorded glucose values before an average value can be calculated, whereas the 
One Touch II has this facility as a function of the meter.
In conclusion, it would appear that the One Touch II and Accutrend blood 
glucose meters have comparable accuracy when used by diabetic patients. 
However, for the majority of patients the One Touch II meter is preferable 
because of its superior ease of use. This study has also shown that the glucose 
values stored in meter memories would seem to be more useful than in-clinic 
random glucose measurements when assessing the glycaemic control of insulin 
treated patients.
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